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Genetic and Pharmacologic Studies Towards Prevention of opioid use disorder  
Shane West Kaski 
 
Endogenous opioids mediate both analgesic and affective responses to stress. While the mu opioid 
receptor (MOR) produces the reinforcing euphoric effects responsible for the high abuse potential of traditional 
opioid analgesics, the kappa opioid receptor (KOR) is hypothesized to mediate the dysphoric component of 
stress. With increasing rates of opioid addiction, extensive research efforts are focused on better understanding 
each of these systems and how they interact, with the goal of developing less addictive pain management 
strategies and better approaches to addiction treatment. With this in mind, we conducted both clinical and pre-
clinical studies aimed at developing better treatment strategies for opioid use and the management of patients 
with opioid use disorder (OUD). First, we assessed a local cohort of patients with (OUD) for a collection of 
single nucleotide polymorphisms (SNPs) related to reward processing, with the goal of furthering efforts to 
develop a gene-based screening mechanism for OUD risk assessment. Second, we conducted preclinical 
assessments of the G protein-biased KOR agonist nalfurafine as a potential adjuvant medication for increasing 
the therapeutic efficacy of opioid-based analgesia. Genetic analysis of OUD patients identified two SNPs within 
the gene encoding the mu opioid receptor, one SNP within the gene encoding the serotonin 2B (5-HT2B) 
receptor, and one SNP within the gene encoding Regulator of G protein Signaling 2 (RGS2), with the frequency 
of each SNP varying significantly from that observed in reference populations of European descent. Preclinical 
investigations with nalfurafine use in mice demonstrated a greater analgesic synergy when co-administered with 
morphine than morphine co-administered with the unbiased KOR agonist U50,488. As G protein-biased KOR 
agonists are hypothesized to produce less dysphoria (a therapeutically limiting side effect of KOR agonists), 
they may present a viable method for reducing the dose of MOR-targeting analgesic necessary for adequate pain 
relief, thereby reducing the likelihood of developing OUD. Further research is necessary to identify any anti-
therapeutic effects of co-administering these two classes of drugs, as well as the range of pain modalities for 
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1 - Introduction 
1.1  - A Brief History of the Opioid Epidemic 
Opium, an extract of the poppy plant, has left its mark on human culture since the plant’s first recorded 
cultivation by the people of Sumeria in 3400 BCE (Rosenblum et al., 2008). As a powerful analgesic producing 
feelings of euphoria, it was used both medicinally and recreationally (Rosenblum et al., 2008) In the early 
1800’s Friedrich Serturner isolated morphine, one of the active chemicals in opium (Wilkerson et al., 2016). 
Morphine saw extensive use during the American Civil War, with subsequent morphine addition developing 
consistently enough that it earned the name “the army disease” (Courtwright, 1978).Not long afterward began 
the pursuit of a non-addictive substitute for morphine, with Charles Wright’s synthesis of diacetylmorphine 
(Wilkerson et al., 2016). Today, diacetylmorphine is an illicit drug more commonly known as heroin and used 
by nearly 1 million people as reported in the 2016 National Survey on Drug Use and Health. Without a non-
addictive replacement, opioid analgesics were largely avoided outside of acute and cancer-related pain until the 
1980s, when a pair of publications claimed to demonstrate little risk of addiction when prescribed to pain 
patients without a history of drug abuse (Porter and Jick, 1980; Portenoy and Foley, 1986; Wilkerson et al., 
2016). As a result, prescribing practices loosened and by the end of the 1990s pain was seen as “the fifth vital 
sign,” with the management of chronic pain even becoming part of the accreditation process for hospitals 
(Phillips, 2000). Released in 1996, OxyContin® (extended release oxycodone) constituted a major portion of 
the increase in opioid prescriptions. The extended release formulation, aggressively marketed as less likely to 
produce addiction, was easily circumvented allowing for large, instant release doses of oxycodone (Remillard et 
al., 2019) and many consider OxyContin to be a central player in the rise of opioid addiction (Dyer, 2014; Jones 
et al., 2017). In 2017, the number of opioid prescriptions neared 200 million (CDC, 2017), while the number of 
opioid use disorder (OUD) diagnoses exceeded 2.1 million (SAMHSA, 2018). 
 Opioid use disorder is defined in the 5th edition of the Diagnostic and Statistical Manual of Mental 





legitimate medical purpose, or at higher doses than therapeutically required, despite “…clinically significant 
impairment or distress.” While this diagnosis is commonly thought of as addiction to the illicit drug heroin, 
roughly 1.67 million of the 2.1 million Americans diagnosed with OUD were using prescription opioids 
(SAMHSA, 2018). While the use of prescription opioids for the treatment of moderate to severe acute and 
cancer-related pain is regarded as standard and necessary (WHO, 1996; Christo and Mazloomdoost, 2008), their 
use in the management of chronic pain is contentious (Rosenblum et al., 2008; Salsitz, 2016).  
Ironically, these long term outpatient prescriptions of opioids for chronic pain constitute the majority of 
the increase in opioid prescriptions (Boudreau et al., 2009; Gomes et al., 2011) and carry with them an 
increased potential for abuse (Shah et al., 2017; Barry et al., 2018; Brat et al., 2018). It is estimated that 
approximately 8-12% of patients on long term opioid therapy for chronic pain will develop OUD (Martell et al., 
2007; Vowles et al., 2015; Volkow and McLellan, 2016) while closer to 25% will engage in “aberrant 
medication-taking behaviors” such as diversion of the medication to other individuals (Martell et al., 2007; 
Vowles et al., 2015; Volkow and McLellan, 2016). Addiction to and misuse of these prescription opioids is also 
linked to the use of heroin, with 80% of new heroin addicts reporting first abusing prescription opioids (Jones, 
2013b). With such a strong correlation to prescription rates, it is hoped that alterations in prescribing practices 
will help curb the rise of OUD (Volkow and McLellan, 2016). A better understanding, however, of why some 
prove more susceptible than others to opioid abuse will be needed to inform truly responsible and effective 
prescribing guidelines. 
 
1.2 - The Genetics of Opioid Addiction 
 Extensive investigation is underway to identify single-nucleotide polymorphisms (SNPs) that predict an 
individual’s likelihood of developing a substance use disorder (SUD) of any kind, including OUD. Currently, 
physicians do no better than chance at predicting which patients abuse opioids (Blum et al., 2018a) and current 
prescribing guidelines focus on generally reducing exposure and screening for a history of substance abuse 





screening patients before initiating opioid therapy to assess their likelihood of abuse and to tailor treatment for 
greatest efficacy. The genetics of SUD and psychiatric disorders in general, however, is complicated and now 
accepted to involve many genes, environmental factors, and gene x environment interactions. The Harvard 
Twin Study of Substance Abuse found that 34% of the variance in all substance abuse was attributable to 
additive genetic effects and that 43% of the variance in opioid abuse specifically was accounted for by additive 
genetic effects (Tsuang et al., 1998). This result is supported by at least one other twin study showing 48% 
genetic association of opioid addiction (Kendler et al., 2003).Though still in its nascency, ongoing research has 
identified several SNPs, found largely within genes expressed in limbic circuits, that correlate with rates of 
OUD and (in some combination) may account for this relationship. 
 
 1.2.1 - mu opioid receptor (MOR) 
 Of the predominant opioid receptors (mu, delta and kappa), MOR, encoded by the gene OPRM1 is the 
primary site of action for opioid analgesics (Basbaum and Fields, 1984a; Pasternak, 1993) and is thus a likely 
site of variability in response to this class of drugs. Bond et al. identified the A118G SNP of the OPRM1 gene 
(rs1799971) as having decreased expression and a greater affinity for its endogenous ligand, b-endorphin (Bond 
et al., 1998). In addition, Zhang et al. showed a reduced abundance of G allele mRNA in eight postmortem 
samples from subjects heterozygous for the A118G SNP, as well as reduced mRNA and protein levels in 
transfected Chinese Hamster Ovarian (CHO) (Zhang et al., 2005b). Human subjects carrying rs1799971 have 
shown increased odds for heroin addiction (Bart et al., 2004), increased nociceptive sensitivity (Tan et al., 
2009), and decreased sensitivity to the analgesic effects of opioids in a post-operative setting (Chou et al., 
2006). A meta-analysis by Haerian and Haerian of 13 studies with more than 9,000 subjects, however, identified 
no increased risk of opioid dependence among Caucasian or African-American subjects but an increased risk in 
Asian subjects with this specific SNP (Haerian and Haerian, 2013). While the A118G SNP remains the most 
well studied, other polymorphisms of MOR demonstrate significant associations with various parameters of 





in a Han Chinese population (Xu et al., 2014), while SNPs rs510769 and rs3778151 in Caucasians (Levran et 
al., 2008), along with rs62638690 in people of European ancestry (Clarke et al., 2013), all affect susceptibility 
to heroin addiction. These results support further investigation of MOR polymorphisms as drivers of 
susceptibility to OUD 
 
 1.2.2 - kappa opioid receptor (KOR) 
 The kappa opioid receptor, encoded by the gene OPRK1, plays a strong role in the regulation of negative 
affective states (see section on MOR, KOR and Addiction below) and its endogenous ligand, dynorphin, is 
increased after exposure to opioid drugs (Wang et al., 1999). The OPRK1 SNP rs6473797 demonstrated a 
reduced risk of heroin addiction in Caucasians (Levran et al., 2008) while Yuferov and Kreek showed that the 
G36T transition of rs6473797 correlates with a higher susceptibility to heroin addiction in a mixed population 
(Yuferov et al., 2004). Evidence exists that at least one polymorphism in OPRK1, rs16918875, may increase the 
risk of heroin addiction in patients who also possess the A118G SNP of OPRM1 beyond that conferred by either 
SNP alone (Kumar et al., 2012), hinting at a complex interplay of genetic susceptibilities underlying OUD. 
Various SNPs have also been identified in the gene encoding prodynorphin, the precursor of the endogenous 
KOR agonist dynorphin, PDYN. The majority of these PDYN SNPs, such as rs35286281 (Wei et al., 2011) and 
rs1022563 (Clarke et al., 2012), result in decreased expression of PDYN mRNA, as assessed both in vitro and in 
post-mortem analysis of human samples (Yuferov et al., 2004). These genetic variations in both OPRK1 and the 
gene encoding its cognate agonist, PDYN, demonstrate the potential importance of this KOR signaling system 
in the development of addiction and thus is examined further in later sections. 
 1.2.3 - Delta Opioid Receptor (DOR) 
 Encoded by the gene OPRD1, the delta opioid receptor has been the subject of fewer studies identifying 
polymorphisms in human subjects with OUD, although preclinical data do support a role for DOR signaling in 
altering the rewarding properties of MOR targeting analgesics (Suzuki et al., 1996; Shippenberg et al., 2009). 





heroin addiction in Caucasians (Levran et al., 2008; Nelson et al., 2014) while a third group found a correlation 
between OPRD1 SNP rs508448 and earlier age of heroin use in a population of Han Chinese (Gao et al., 2017). 
These initial population studies, along with the available preclinical evidence, support further investigation into 
variations in OPRD1 and their relationships to the development of OUD. 
 
 1.2.4 - Serotonin Receptors (5HTR) 
 The serotonin (5-hydroxytryptamine) receptors are a large group, with 14 distinct receptors from seven 
different families (Barnes and Sharp, 1999); variations in the genes HTR1B, HTR2A and HTR3A/B (encoding 
the 5-HT1B, 5-HT2A, and 5-HT3 receptors respectively) have shown correlations with heroin addiction. The G 
allele of the G861C variant of HTR1B (rs6296) correlated with heroin addiction, as well as amount of heroin-
injection, in a study of a Han Chinese population (Gao et al., 2011), while a meta-analysis of studies assessing 
HTR1B SNPs for relationships with substance abuse found that rs130058 significantly correlated with heroin 
dependence in a mixed population (Cao et al., 2013). The A allele of the A1438G polymorphism (rs6311) of 
HTR2A correlates with heroin dependence in one study of a population in Spain (Saiz et al., 2008), while SNPs 
within HTR3B (rs3758987) (Levran et al., 2008) and HTR3A (rs1176724 and rs897687) (Levran et al., 2009) 
show correlations with heroin addiction in Caucasian and African-American populations, respectively. 
Although all these reports involve serotonin receptors, their individual biological functions vary significantly, 
and thus further research is needed to elucidate the role of each of these polymorphisms in increasing 
susceptibility to OUD. 
   
 Taken together, the studies outlined above support the genetic association seen in OUD, while at the 
same time make obvious the nascency of this line of research. Such factors as patient stratification, statistical 
analysis and lack of replication make it difficult to draw strong conclusions from the present reports. These 
findings, however, along with future advances in both genetic and epidemiologic methods, should encourage 






 1.3 - MOR, KOR, and Addiction 
 The opioid family of neuron signaling-inhibitory G protein-coupled receptors (GPCRs) not only 
includes the “classical” mu, kappa, and delta opioid receptors, but also the “non-classical” Nociceptin receptor. 
While all have been shown to modulate certain aspects of opioid-induced behaviors in rodent studies, MOR and 
KOR are thought to exhibit the strongest influence on the development of addiction (Koob and Le Moal, 1997; 
Crowley and Kash, 2015; Chavkin and Koob, 2016; Koob and Volkow, 2016). Opioid painkillers target 
primarily the mu opioid receptor, agonism of which produces both analgesia and euphoria (Koob and Le Moal, 
1997; Koob and Volkow, 2016). Activation of the kappa opioid receptor produces analgesia as well (albeit more 
weakly), and carries with it clinically limiting effects, such as dysphoria and psychotomimesis (Pfeiffer et al., 
1986; Siebert, 1994; Greenwald and Stitzer, 1998; Kivell and Prisinzano, 2010). The following sections outline 
the neurobiology of each of these opioid receptors as they relate to analgesia as well as the development and 
maintenance of opioid addiction. 
 
1.3.1 - Analgesia 
The clinical success of MOR-targeting analgesics arose from their activity at both spinal and supraspinal 
sites. At the level of the spinal cord, MOR localizes to both the presynaptic terminal of primary nociceptive 
afferents transmitting pain signals into the spinal cord (Fields and Basbaum, 1978; Pasternak, 1981; Moriwaki 
et al., 1996; Kline and Wiley, 2008; Todd, 2010b), as well as the post-synaptic cell bodies of secondary 
nociceptive efferents transmitting pain signals to higher brain centers (Moriwaki et al., 1996; Kline and Wiley, 
2008; Todd, 2010b). MOR activation also modulates pain signals through its activity in the periaqueductal gray 
(PAG) matter (Basbaum and Fields, 1978; Yaksh et al., 1980; Basbaum and Fields, 1984b; Ghelardini et al., 
2015b), a midbrain region that controls numerous functions, from fear and anxiety responses to blood pressure 






The PAG modulates pain by controlling projections from midbrain nuclei to the dorsal horn of the spinal 
cord, a descending pathway that inhibits nociception (Basbaum and Fields, 1978; Yaksh et al., 1980; Basbaum 
and Fields, 1984b; Behbehani, 1995; Ghelardini et al., 2015b). This pathway begins in the periaqueductal gray, 
where glutamatergic neurons projecting to serotonergic and noradrenergic cell bodies in the rostral 
ventromedial medulla (RVM) (Basbaum and Fields, 1978; Yaksh et al., 1980; Basbaum and Fields, 1984b; 
Behbehani, 1995; Ghelardini et al., 2015b) remain under tonic inhibition by a local GABAergic circuit 
(Basbaum and Fields, 1978; Yaksh et al., 1980; Basbaum and Fields, 1984b; Behbehani, 1995; Ghelardini et al., 
2015b). Activation of MORs located on the GABAergic neurons of the PAG leads to disinhibition of the 
glutamatergic projection neurons, in turn stimulating the serotonergic and noradrenergic neurons of the RVM 
(Pasternak, 2005b; Ghelardini et al., 2015b). These RVM neurons then project to the dorsal horn of the spinal 
cord, wherein release of serotonin and norepinephrine inhibit transmission of nociceptive signals (Pasternak, 
2005b; Ghelardini et al., 2015b). In this way, MOR-targeting analgesics prevent the transmission of nociceptive 
signals directly, through actions at receptors in the dorsal horn, and indirectly through the modulation of 
regulatory projections. 
The role of KOR signaling in producing spinal analgesia is similar to MOR activation outcomes, as the 
distribution of KOR resembles that of MOR (Besse et al., 1990; Todd, 2010b; Stein, 2016b) and KOR 
activation serves to inhibit the transmission of nociceptive signals through the dorsal horn (Todd, 2010a; Stein, 
2016a). In the PAG and descending pain-inhibitory circuit, however, the role of KOR remains unclear. For 
example, one study found that microinjection of pentazocine, a KOR agonist, into the PAG produced analgesia 
against noxious heat but not against pressure, while fentanyl, a MOR-selective agonist, produced analgesia 
against both pain modalities (Llewelyn et al., 1983). A second group, however, used a thermal stimulus to show 
that morphine (a MOR-selective agonist), but not U50,488 (a KOR-selective agonist), produced an analgesic 
effect when microinjected directly into the PAG (Llewelyn et al., 1983). In addition to being a KOR agonist, 





(Clark and Pasternak, 1988; Hoskin and Hanks, 1991). This difference likely explains the disparate results 
between these two studies. 
As a further complication, the distribution of MOR and KOR in these descending circuits remains 
unclear. While overlap may exist in their distribution, as reported in some histological studies (Gutstein et al., 
1998), others demonstrate that MOR and KOR act in specific subpopulations of neurons in the RVM (Pan et al., 
1997; Winkler et al., 2006), and that this distribution produces opposing analgesic effects (Pan et al., 1997; 
Tershner et al., 2000; Bie and Pan, 2003) (discussed further below). These discrepancies may also contribute to 
reported differences regarding receptor signaling effects on particular pain modalities. While less potent for 
somatic pain, KOR agonists display a greater potency for visceral pain in both preclinical studies (Su et al., 
2002; Kamp et al., 2003) and in a clinical trial using a peripherally restricted KOR agonist (Arendt-Nielsen et 
al., 2009). As the underlying mechanisms and circuitry of somatic and visceral pain differ (Cervero and Laird, 
1999), it is possible that these ambiguities in the distribution of each receptor play a role in their differing 
effects. 
Finally, the variable of sex plays a large role in opioid analgesia. While it was long held that opioid 
analgesics produced greater analgesia in human females (Miaskowski and Levine, 1999), more recent studies 
complicate the issue, showing not only a greater degree of opioid-induced analgesia in males than in females, 
but also that these results vary depending on the opioid analgesic used, the type of pain, and the method used to 
assess pain/opioid efficacy (Gourlay et al., 1988; Cepeda and Carr, 2003; Miller and Ernst, 2004; Fillingim et 
al., 2005; Sibille et al., 2011; Lee and Ho, 2013). A 2010 meta-analysis of fifty studies found no association 
between sex and analgesia, although sub-group analysis found greater morphine-induced analgesia in women 
(Niesters et al., 2010). Studies of KOR-agonist induced analgesia produce the most reliable findings, repeatedly 
demonstrating greater analgesic efficacy in human females compared with males (Gear et al., 1996; Fillingim 
and Gear, 2004; Miller and Ernst, 2004). As a further complication, results from preclinical experiments on rats 
and mice show that both MOR-targeting and KOR-targeting opioid analgesics prove more efficacious in males 





While both MOR and KOR produce analgesia through their activities in the spinal cord and descending 
pain-modulatory pathways, MOR agonists provide greater analgesia than KOR agonists due to their functional 
divergence in higher brain centers. Compared with KOR agonists, MOR-targeting analgesics retain broad 
applicability to nearly all types of pain, in part because of their ability to produce euphoria, thereby reducing the 
affective component of pain and preventing “agony” even when the conscious perception of a nociceptive 
stimulus remains (Zubieta et al., 2005; Porreca and Navratilova, 2017a). This ability, however, also leads to the 
dramatic abuse potential of MOR-targeting analgesics. In contrast, KOR agonism produces anxiety and 
dysphoria, limiting the clinical utility of KOR agonists and playing a major role in the cycle of addiction 
through its role in the production of negative affect. The following sections explore the effects of MOR and 
KOR agonism on affective state and motivation with respect to the development of addiction. 
 
1.3.2 - Euphoria and Dysphoria  
Both mu and kappa opioid receptors play central roles in the cycle of addiction. While MOR activation 
figures prominently in the initial development of drug preference through its euphorigenic properties (Koob and 
Le Moal, 1997; Koob and Volkow, 2016), KOR activation reinforces habitual drug taking through its dysphoric 
properties, producing a state of negative affect and “emotional pain” (Koob and Le Moal, 1997; Bruchas et al., 
2010; Koob, 2013). In the CNS, these two receptors normally function in opposition to produce an affective 
homeostasis. When perturbed, however, this system may spiral to lower and lower set-points, leading to the 
destructive cycle of drug seeking known as addiction. 
 
1.3.2a - Euphoria, reward and the mu opioid receptor  
While MOR expression is distributed widely throughout the brain, the highest levels of MOR expression 
are found in regions involved in pain processing (notably the thalamus and periaqueductal gray matter) and 
motivated behavior (the mesolimbic system) (Le Merrer et al., 2009), with the latter playing the strongest role in 





the hypothalamus as well as the nucleus tractus solitarius (Froehlich, 1997), and is distributed throughout the 
brain as a homeostatic mechanism of reducing stress and producing reward, being released in response to novel 
stimuli as well as in times of stress and exercise (Rubinstein et al., 1996; Goldfarb and Jamurtas, 1997; Veening 
and Barendregt, 2015). As such, the mu opioid receptor system largely produces a positive affective response 
and motivates behavior through its effects on the mesolimbic system. 
The mesolimbic pathway comprises dopaminergic projections from the ventral tegmental area (VTA) to 
the nucleus accumbens (NAc) and plays a key role in reward prediction, in addition to encoding the incentive 
salience of natural rewarding stimuli (Fields and Margolis, 2015). When encountering a rewarding stimulus, 
ranging from basic rewards like food to complex social rewards such as praise, burst firing of the VTA releases 
dopamine in the NAc and produces a positive reinforcement of the behavioral pattern that produced the 
rewarding stimulus (Bromberg-Martin et al., 2010; Salamone and Correa, 2012). VTA dopamine neurons 
remain under tonic inhibition by local GABAergic interneurons that express mu opioid receptors (Leone et al., 
1991; Johnson and North, 1992). Endogenous opioid release in this area serves to inhibit these GABAergic 
interneurons, leading to disinhibition of VTA dopaminergic projections to the NAc, producing positive 
reinforcement (Leone et al., 1991; Johnson and North, 1992). Strong evidence supports this action on VTA mu 
opioid receptors as the primary mechanism of opioid analgesic induced reward (Leone et al., 1991; Fields and 
Margolis, 2015; Valentino and Volkow, 2018). Place preference for MOR-targeting analgesics is blocked in rats 
by administration of a MOR antagonist directly into the VTA (Olmstead and Franklin, 1997); conversely, MOR 
agonists are self-administered by rats when applied directly to the VTA (Bozarth and Wise, 1981; Zangen et al., 
2002). While animals will self-administer MOR agonists applied to several other brain regions as well (David 
and Cazala, 1994), their actions in the VTA are widely regarded as necessary and sufficient for the reinforcing 
properties of opioid analgesics (Fields and Margolis, 2015). Furthermore, disinhibition of dopamine release 
likely plays a role in the ability of MOR-targeting opioid analgesics to reduce the affective experience of pain, 
as decreased function of midbrain dopaminergic neurons leads to increased pain (Saadé et al., 1997; Sophie and 





(dopamine deficient mice) show reduced thermal nociception in the tail withdrawal assay in response to 
morphine, supporting the role of dopaminergic signaling in the analgesic response to traditional opioid 
analgesics (Hnasko et al., 2005). 
This canonical model, however, is not without its complications. Destruction of dopaminergic 
projections from the VTA to the anterior cingulate cortex (ACC), for example, blocks the acquisition of place 
preference to morphine administered to rodents systemically as well as directly into the VTA, implicating 
mesocortical circuitry in opioid reinforcement (Narita et al., 2010). In addition, while dopamine antagonists 
may block acquisition of morphine-induced place preference, the potency of this effect varies with the 
specificity of the antagonist for the various subtypes of dopamine receptor (Manzanedo et al., 2001). More 
confounding still are findings dopamine deficient mice (lacking functional tyrosine hydroxylase) still display a 
place preference to morphine (Hnasko et al., 2005), implicating factors beyond dopaminergic signaling in 
producing opioid reward.  
While the intricacies of dopamine signaling in addiction require further inquiry, the initial phase of the 
development of opioid addiction -- acute reward and euphoria -- remain best explained by disinhibition of 
mesolimbic circuitry. The ability of opioid analgesics to potently disinhibit this circuitry underpins both their 
profound analgesic potential and their devastating propensity to incentivize compulsive use. As such a powerful 
circuit, the brain employs potent means of regulation, none linked more tightly to the cycle of addiction than the 
kappa opioid receptor. 
 
1.3.2b - Dysphoria, altered set-points and the kappa opioid receptor 
While the distribution of kappa opioid receptors mirrors that of MOR in many regions, oppositional 
localization in specific regions produces profound differences in the effect of KOR stimulation (Le Merrer et 
al., 2009). While stimulation of MORs produces euphoria, activation of KORs produces dysphoria, a negative 
affective state that includes components of anxiety, anhedonia, and depressive symptoms (Knoll and Carlezon, 





Dynorphin, a neuropeptide cleaved to six different lengths from the precursor prodynorphin and the 
endogenous ligand of the kappa opioid receptor, is produced in the hypothalamus (Froehlich, 1997), the 
amygdala (Marchant et al., 2007), and direct pathway GABAergic medium spiny neurons of the striatum 
(Steiner and Gerfen, 1998) (among other regions), and is released in response to stress (Knoll and Carlezon, 
2010). Unlike b-endorphin, however, dynorphin plays the role of a negative homeostatic regulator. Dynorphin 
produces the negative experiences of stress (Land et al., 2008) and plays a role in mediating the central effects 
of corticotropin releasing factor (CRF), a major hormonal regulator of the stress response (Land et al., 2008). 
The areas most heavily implicated in the production of this negative state include the VTA-to-NAc circuit, 
along with the amygdala and dorsal raphe nucleus (DRN), the latter being the major serotonergic nucleus of the 
brain (Luo et al., 2015). In each of these regions, activation of KOR produces effects largely in opposition to 
those of MOR, culminating in the overall negative affective state of dysphoria. 
In the mesolimbic system, KOR activation functions to reduce dopamine release, with KOR expression 
found on both the cell bodies of dopaminergic VTA neurons, as well as the presynaptic terminals of these 
neurons within the NAc (Figure 1) (Svingos et al., 2001; Chefer et al., 2013; Ehrich et al., 2015a). In both these  
 
Figure 1.3.2b.1. Schematic of KOR and MOR receptors in mesolimbic pathway. 
Activation of MORs on GABAergic interneurons of the VTA disinhibits dopamine release, 






regions, KOR activation acts as negative feedback regulation on mesolimbic dopamine release, serving 
to restore homeostatic function within this circuit. When dopamine D1 receptor (D1R)-expressing neurons 
within the NAc are stimulated by dopamine, they release both dynorphin and GABA from axonal projections 
terminating in the VTA to reduce the firing rate of the dopaminergic neurons located therein (Nestler and 
Carlezon, 2006; Mysels and Sullivan, 2009). As disinhibition of this circuitry by MOR agonists produces a 
rewarding stimulus, inhibition by KOR agonists produces the opposite (i.e., aversion, as measured in rodents in 
the conditioned place aversion (CPA) paradigm (Chefer et al., 2013; Ehrich et al., 2015a)); as a result, KOR 
agonists do not support self-administration in rats or rhesus monkeys (Tang and Collins, 1985; Serra et al., 
2015; Ruan et al., 2016). Recent studies have strongly linked these aversive properties of KOR agonists to 
actions on mesolimbic dopamine neurons (Chefer et al., 2013; Ehrich et al., 2015a). 
KOR actions in the amygdala appear to play a role in modulation of fear and anxiety related behaviors, 
possibly through modulation of local GABAergic neurotransmission and long-term potentiation (Huge et al., 
2009; Kang-Park et al., 2013; Gilpin et al., 2014). Fear conditioning in rats is reported to increase OPRK1 
mRNA in this region, and local inhibition of KORs reduces this response (Knoll et al., 2011). In addition, KOR 
antagonism in the amygdala blocks the anxiogenic effect of a natural stressor (repeated forced swim stress) or 
intra-amygdalar injection of CRF in the elevated plus maze (EPM) assay (Bruchas et al., 2009). The DRN also 
plays a central role in mediating the affective response to KOR agonists. Stimulation of KORs in this region 
reduces extracellular serotonin concentration (Tao and Auerbach, 2005), likely through increasing surface levels 
of the serotonin transporter (SERT) via a p38a MAPK dependent mechanism (Bruchas et al., 2011), an effect 
seen in mice after both local administration of a KOR agonist and social defeat stress (Bruchas et al., 2011). 
Furthermore, while the KOR agonist U50,488H did not produce a place aversion in mice lacking the kappa 
opioid receptor, viral re-expression of KORs on DRN neurons projecting to the NAc restored the effect in these 
KOR knockout mice (Land et al., 2009a).  
The effects of KORs within these specific brain regions support the view that the dynorphin/KOR 





Chavkin and Koob, 2016). Dynorphin levels increase due to stress (Nabeshima et al., 1992), and blockade or 
genetic deletion of OPRK1 in mice prevents the pro-depressive and anxiogenic effects of forced swim, social 
defeat, and foot-shock stressors (Mague et al., 2003; Land et al., 2008; Bruchas et al., 2009; Bruchas et al., 
2011). Systemic administration to rodents of KOR agonists produces a place aversion (Zhang et al., 2005a; 
Chefer et al., 2013) and depressive-like phenotypes in the forced swim and intra-cranial self-stimulation (ICSS) 
assays (Todtenkopf et al., 2004; Carlezon et al., 2006; Brust et al., 2016b). By producing these negative 
affective states, the dynorphin/KOR system also figures heavily into the addictive cycle. Stressful stimuli 
reinstate extinguished drug seeking behaviors in both place preference and self-administration paradigms 
(Mantsch et al., 2016). Pre-treatment of mice with the KOR antagonist nor-binaltorphimine (norBNI), as well as 
genetic deletion of either OPRK1 or PDYN, prevented the reinstatement of cocaine conditioned place preference 
(CPP) by foot shock or forced swim stressors, as well as to a single administration of U50,488H (Redila and 
Chavkin, 2008). In addition, CPP for cocaine increased in mice exposed to forced swim stress prior to 
conditioning, an effect blocked by pre-treatment with norBNI (McLaughlin et al., 2003). While KOR 
antagonism also reduced ethanol self-administration by rats (Walker and Koob, 2008), the applicability to other 
drugs of abuse requires further investigation. 
In light of its role in regulating limbic function and mediating stress responses, the kappa opioid receptor 
should be viewed as a key component of the “Allostatic Model” of addiction (Koob and Le Moal, 2001; Koob 
and Schulkin, 2018). This model contextualizes the state of addiction as one of a pathologically altered 
homeostatic set point, or “allostasis” (McEwen, 1998; Koob, 2008). The dynorphin/KOR system contributes to 
this allostatic response largely through modulation of dopamine tone within the mesolimbic system (Bruchas et 
al., 2010; Koob, 2013). As described above, MOR-targeting analgesics increase dopaminergic tone in the NAc, 
a property common to nearly all drugs of abuse (Wise, 2009; Koob and Volkow, 2016). Repeated use results in 
increased production of cAMP response element binding protein (CREB) within the NAc (Carlezon et al., 2005; 
Nestler and Carlezon, 2006) and subsequent upregulation of dynorphin and increased dynorphin tone (Nestler 





elevated dynorphin tone leads to a state of dysphoria, increasing the hedonic valence of the drug and increasing 
the susceptibility of relapse in an attempt to attain the now pathologically altered homeostatic set point (Bruchas 
et al., 2010; Koob, 2013; Koob and Schulkin, 2018). 
In summary, while activation of both mu and kappa opioid receptors produces analgesia in response to 
stressful stimuli, the psychological functions of the receptors diverge dramatically and represent the opposing 
faces of opioid addiction. The desire of clinicians to alleviate pain placed the profound effects of MOR 
stimulation at the forefront of medicine in the early 2000s. Today, KOR antagonists sit among the National 
Institute of Drug Abuse (NIDA)’s ten most wanted drugs to help end the opioid crisis (Rasmussen et al., 2019), 
with the thought that the clinical application of KOR antagonism might reduce the contribution of stress, and its 
molecular and circuitry sequelae, in drug seeking and addiction reinstatement. 
 
 
1.4 - Pharmacological approaches for improving opioid analgesics 
 The search for a non-addictive opioid analgesic began nearly the moment Friedrich Serturner first 
isolated morphine in the early 1800’s (Wilkerson et al., 2016), and the search regrettably continues today, over 
200 years later. Many opioids are sold today as combination drugs, compounding opioids with non-steroidal 
anti-inflammatories like ibuprofen and acetaminophen as adjuvants meant to reduce the dose of opioids 
necessary to effectively treat pain, otherwise known as “dose sparing” (Remy, 2005; Maund et al., 2011). Other 
adjuvant therapies, such as suboxone, focus on preventing improper use of opioid medications by compounding 
them with opioid antagonists active only when taken through improper routes (Chen et al., 2014), but the effect 
of these measures are unclear. While many approaches are currently being investigated in labs across the world, 
from targeting little-understood splice-variants of the mu opioid receptor (Xu et al., 2017) to designing opioids 
that function only in the presence of inflammation (Spahn et al., 2017), the following sections focus on two 
widely studied and promising avenues: combination therapies activating multiple opioid receptors, and the 






 1.4.1 - Combining MOR and KOR Activation 
In the 1990s, researchers began investigating the possibility of utilizing the analgesic and non-
reinforcing properties of KOR agonists to augment the effects of traditional MOR agonists. While KOR 
agonists alone proved less potent in producing analgesia (Pizziketti et al., 1985; Briggs et al., 1998), the 
combination of fentanyl (MOR agonist) with U69593 (KOR agonist) showed additive analgesic effects in 
rhesus monkeys while also reducing self-administration levels (Negus et al., 2008a). Further studies 
demonstrated that combined administration of MOR and KOR agonists prevented development of the clinical 
liabilities of opioid tolerance, hyperalgesia, and respiratory depression (He and Lee, 1997; Verborgh et al., 
1997; Black and Trevethick, 1998; Field et al., 1999; Khotib et al., 2004) 
 While pre-clinical experiments demonstrated the utility of combined agonism of each of these opioid 
receptors, enthusiasm for this approach waned in the face of early clinical experiments utilizing mixed 
MOR/KOR active compounds. For example, while nalbuphine (a KOR agonist and MOR partial agonist) 
demonstrated reduced morphine-induced CPP and enhanced analgesia in pre-clinical studies (Tao et al., 2006), 
human studies demonstrated dose-dependent increases in dysphoria (Jasinski and Mansky, 1972; Preston et al., 
1989a; Walsh and Babalonis, 2017). Also, pentazocine (similar to nalbuphine) and butorphanol (a KOR agonist 
and MOR antagonist) demonstrated the classic dysphoric effects of traditional KOR-targeting agonists in 
humans at higher doses (Preston et al., 1987; Zacny et al., 1994; Greenwald and Stitzer, 1998; Walsh et al., 
2008; Walsh and Babalonis, 2017), limiting their therapeutic potential.  
Of note, however, is one report (Preston and Bigelow, 1993) that co-administration of the opioid receptor 
antagonist naltrexone with pentazocine in human subjects “unmasks” the KOR-related dysphoric effects of 
pentazocine at lower doses, but blocks both MOR-dependent and KOR-dependent effects at higher doses. As 
the antagonist naltrexone possesses greater affinity for mu than kappa opioid receptors, these results of Preston 
& Bigelow  support the premise that MOR agonism can mitigate KOR-related anti-therapeutic effects to some 





formulation, these studies demonstrate that relative activity at each receptor plays a critical role in the 
interaction between these two receptor systems. Studies in patients receiving methadone maintenance therapy 
demonstrate that administration of nalbuphine, pentazocine, or butorphanol can precipitate a withdrawal 
syndrome (Preston et al., 1988; Preston et al., 1989b; Strain et al., 1993), indicating that none of these three, 
mixed-action drugs achieves activity at MOR comparable to methadone. While new mixed MOR/KOR drugs 
under development may possess more favorable activity profiles, such as the orvinols and 6b-
naltrexamines (Cami-Kobeci et al., 2009; Greedy et al., 2013), a co-administration paradigm may allow for 
greater control over relative activity at each receptor. 
With these clinical studies dampening the potential therapeutic implications for KOR agonist development, 
research efforts dwindled. The rise of opioid addiction rates, however, has reinvigorated interest in the kappa 
opioid receptor. Cara Therapeutics invested heavily in developing a peripherally restricted KOR agonist, and its 
novel compound, CR845/difelikefalin is currently in Phase III clinical trials (Cara, 2018). In addition to 
peripheral restriction of KOR agonism (i.e., to gain analgesic effect without concomitant CNS-centered 
dysphoric effects), major preclinical research efforts focus on utilizing a relatively new concept in 
pharmacology known as “biased agonism.” This approach utilizes variations in the efficacy of different 
compounds to engage various aspects of intracellular machinery, designing drugs that differ in their ability to 
produce canonical effects associated with receptor stimulation. 
 
 1.4.2 - Biased Agonism: All the good and none of the bad? 
G protein-coupled receptors regulate an astoundingly diverse array of physiological processes and represent 
the target of approximately 37% of all drugs approved by the FDA as of 2017 (Hauser et al., 2017). 
Structurally, GPCRs contain seven transmembrane domains that couple to a heterotrimeric complex of Ga,b 
and g subunits on the intracellular face (McCudden et al., 2005). The Ga subunit of this heterotrimeric complex 
associates with guanine nucleotide diphosphate (GDP) in the resting (inactive) conformation. When bound by 





which point the Ga subunit bound to GTP dissociates from the Gbg obligate heterodimer (McCudden et al., 
2005). Both the Ga-GTP and Gbg complexes initiate signaling cascades that vary depending upon the receptor 
and cellular context and are considered “G protein dependent” as a whole (McCudden et al., 2005). All opioid 
receptors couple to the Gai/o class of Ga proteins. (Connor and Christie, 1999; Stein, 2016a). The Gi/o 
heterotrimeric complex, when activated (and separated) by GTP binding, generally functions to inhibit the 
production of cyclic adenosine monophosphate (cAMP), as well as increase potassium conductance 
(hyperpolarizing the cell) and inhibit calcium conductance (preventing vesicular release of neurotransmitters) 
(Pasternak, 2005a; Al-Hasani and Bruchas, 2011; Ghelardini et al., 2015a). Activation of opioid receptors 
inhibits neuronal function through these G protein-dependent mechanisms. 
In addition to G protein-dependent signaling, work in the 1990’s demonstrated that GPCRs also initiate 
signaling cascades through a class of proteins known as b-arrestins (Wisler et al., 2014). Canonically, when a 
Gbg subunit dissociates from Ga-GTP upon agonist binding and receptor-catalyzed nucleotide exchange, it may 
activate a class of proteins known as G protein-receptor kinases (GRKs) (McCudden et al., 2005). This class of 
proteins serves to phosphorylate activated GPCRs, subsequently leading to the recruitment of b-arrestin 
(McCudden et al., 2005; Wisler et al., 2014). One of the functions of b-arrestin proteins is to act as a molecular 
brake on GPCR signaling, leading to the cessation of further G protein heterotrimer activation and subsequent 
receptor internalization. The internalized b-arrestin/GPCR complex then activates signaling pathways distinct 
from those activated by G protein subunits (Raehal, 2005; Wisler et al., 2014).  
When a GPCR agonist compound activates either the G protein-dependent or b-arrestin dependent pathway 
to a greater extent than the other, this agonist is considered “biased” towards that signaling pathway (Wisler et 
al., 2014). Research in recent years demonstrates that the physiological and behavioral effects classically 
associated with stimulation of specific GPCRs may occur to a greater or lesser extent upon the application of 





possibility of discovering opioid drugs that lack traditional adverse effects has led to a surge in research focused 
on biased MOR and KOR compounds. 
 
1.4.2a - G protein-biased MOR agonists 
At the mu opioid receptor, G protein-dependent signaling produces the intended analgesic response (Todd, 
2010a; Stein, 2016a), while b-arrestin signaling governs many of the unwanted side-effects. As might be 
predicted by the function of b-arrestin, mice lacking BARR2, the gene encoding b-arrestin2, displayed a 
decrease in the development of opioid analgesic tolerance and prolonged analgesic responses to morphine 
(Bohn, 1999; Bohn et al., 2000). In addition, BARR2 knockout (KO) mice also display reduced respiratory 
depression and constipation after morphine administration (Raehal, 2005). Loss of b-arrestin2 did not, however, 
affect the development of naloxone-precipitated withdrawal symptoms (Bohn et al., 2000) or of morphine-
induced hypothermia (Bohn, 1999). Pursuit of a G protein-biased MOR agonist led to the development of 
TRV130 (oliceridine), which shows potent analgesic effects and reduced tolerance development in rodents, yet 
retains the clinical liability of inhibitory effects on GI motility (Altarifi et al., 2017). Importantly, TRV130 also 
displays robust reinforcing effects, linking abuse liability to G protein-dependent signaling (Altarifi et al., 2017; 
Negus and Freeman, 2018). Despite these pre-clinical findings, TRV130 has proceeded to clinical trials as a 
potent opioid with reduced likelihood of requiring escalating doses due to a decreased propensity to induce 
tolerance.  
A Phase I, double-blind, placebo-controlled study comparing morphine with TRV130 reported that the latter 
drug exhibited analgesic efficacy with reduced respiratory depression at equianalgesic doses, as well as a lower 
incidence of severe nausea (Soergel et al., 2014). While the FDA Advisory Committee stated that oliceridine 
demonstrated a “favorable benefit/risk profile” and proved superior to placebo in both APOLLO-1 and 
APOLLO-2 Phase III  clinical trials (Research, 2018), the Anesthetic and Analgesic Drug Products Advisory 
Committee did not grant FDA approval to oliceridine, stating that “…oliceridine is a mu opioid agonist with an 





opioid agonists” (FDA, 2018). As stated by this same report, “…it does not appear that the biased agonism of 
oliceridine with regard to preferential recruitment of G-protein over b-arrestin2 translates into a human safety 
advantage…” (FDA, 2018). Although the G protein signaling-biased TRV130 is only the first drug of its kind to 
undergo FDA review, these statements demonstrate not only the significant focus of the FDA on abuse potential 
with regard to opioid drugs, but also the difficulties of translating preclinical findings into human subjects. 
1.4.2b - G protein-biased KOR agonists 
  At the kappa opioid receptor, G protein-dependent signaling also produces analgesic effects through 
inhibition of pain transmission through the dorsal horn of the spinal cord (Todd, 2010a; Stein, 2016a). In 
contrast, a strong arc of research implicates b-arrestin2 signaling in the therapeutically limiting dysphoric 
effects of KOR agonists (Bruchas et al., 2006; Bruchas et al., 2007a; Ehrich et al., 2015b). As discussed above, 
natural stressors such as forced swim, activate kappa opioid receptors in mice. It has been reported that 
pharmacological inhibition of p38, a mitogen activated protein kinase (MAPK) downstream of ß-arrestin2 
signaling at KOR (Bruchas et al., 2006), with SB203580, or preventing b-arrestin2 recruitment to activated 
KOR through gene deletion of the gene encoding the upstream GRK3 (GRK3), prevents the dysphoric 
component of this stress (Bruchas et al., 2007a). Furthermore, deletion of the gene encoding p38-a (MAPK14) 
from dopamine neurons prevents conditioned place aversion (CPA) in mice to the unbiased KOR agonist 
U50,488 (Ehrich et al., 2015b). These results and others have spurred investigation into a “non-dysphoric” 
replacement of traditional MOR-targeting opioid analgesics with a single KOR agonist biased toward G protein 









The G protein-biased KOR agonist triazole 1.1 did not suppress ICSS thresholds, reduce NAc dopamine 
release, or inhibit novelty-induced locomotion at doses producing analgesia equivalent to U50,488 (Brust et al., 
2016a). These results support the hypothesis that a G protein-biased KOR agonist would not produce the 
sedative and dysphoric effects that have limited traditional, unbiased agonist. Another G protein-biased KOR 
agonist, RB-64, however, produced CPA in both wild-type and b-arrestin2 KO mice without inhibiting novelty 
induced locomotion in either genotype (White et al., 2014). These conflicting results demonstrate the nascency 
of this line of research. First, more work is needed to determine if traditional KOR-related behavioral outcomes 
segregate to specific signaling pathways as cleanly as hypothesized. Second, two G protein-biased ligands (as 
assessed in vitro) may produce disparate results in vivo. While the current body of work focuses on G protein 
Figure 1.4.2b.1. Therapeutic potential of G protein-biased KOR agonists. Reducing signaling 
through b-arrestin may allow for the use of KOR agonists by reducing the incidence of therapeutically 





and ß-arrestin pathways, KOR ligands may possess biases in other signaling pathways such as extracellular 
signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) (Jamshidi et al., 2015) that could explain 
differences in their behavioral effects in vivo. In addition, differential expression of intracellular effector 
proteins within different brain regions has been shown to affect the regiospecific signaling efficacy of a biased 
agonist of the D2 dopamine receptor (Urs et al., 2016b), a process likely at work with KOR ligands. 
 
Taken together, these studies reveal the complexities, and potential promise, of developing such signaling-
selective ligands. Specific G protein-biased KOR agonists, such as triazole 1.1, may produce analgesia without 
producing sedative or dysphoric side effects, while others such as RB-64, may lack sedation but not dysphoria. 
A great deal more research into this field of behavioral pharmacology is required to disentangle the 
complexities of such biased ligands and their potential utility as replacements for traditional MOR-targeting 
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Objective: Pilot study to assess utility in opioid use disorder (OUD) of a panel of single nucleotide 
polymorphisms in genes previously related to substance use disorder (SUD) and/or phenotypes that predispose 
individuals to OUD/SUD. 
Design: Genetic association study. 
Setting: West Virginia University’s Chestnut Ridge Center Comprehensive Opioid Abuse Treatment (COAT) 
clinic for individuals diagnosed with OUD. 
Patients: Sixty patients 18 years of age or older with OUD undergoing medication (buprenorphine/naloxone)-
assisted treatment (MAT); all sixty patients recruited contributed samples for genetic analysis. 
Outcome Measure(s): Minor allele frequencies for single nucleotide polymorphisms. 
Results: Four of the fourteen single nucleotide polymorphisms examined were present at frequencies that are 
statistically significantly different than in a demographically-matched general population. 
Conclusions: For the purposes of testing WV individuals via genetic means for predisposition to OUD, at least 
four single nucleotide polymorphisms in three genes are likely to have utility in predicting susceptibility. 
Additional studies with larger populations will need to be conducted to confirm these results before use in a 
clinical setting. 
 
Keywords: Opioid use disorder (OUD), substance use disorder (SUD), single nucleotide polymorphisms 











 Opioid use disorder (OUD) has reached epidemic proportions in America (Rudd et al., 2016; McBain et 
al., 2018). Non-medical use of opioid analgesics and heroin is on the rise (Fischer et al., 2014; Jordan et al., 
2017; Pergolizzi et al., 2018). Opioid overdose is now the leading cause of death of people under 50 years old 
(Dowell et al., 2017). Mindful of these developments, many addiction researchers are focusing combatting the 
epidemic with prevention and treatment (Marshalek and Sullivan, 2010; Schmid et al., 2017a; Vashishtha et al., 
2017; Ratycz et al., 2018). A shared aspiration is to obtain an individual’s genetic “fingerprint” and identify 
whether they are at increased risk for developing OUD (e.g., ref. (Blum et al., 2018b)). Such testing is likely to 
interrogate several genes, as a multitude of factors (Lu et al., 2003; Badiani and Robinson, 2004; Scherbaum 
and Specka, 2008; Valentine and Fraser, 2008; Ducci and Goldman, 2012; Kreek et al., 2012; Nielsen and 
Kreek, 2012; Mistry et al., 2014; Bawor et al., 2015; Curtis et al., 2017; Crist et al., 2018; Fonseca and Torrens, 
2018) contribute to OUD predisposition. Several gene variations are associated with predisposition to OUD 
and/or OUD treatment response (Kreek et al., 2012; Bawor et al., 2015; Curtis et al., 2017; Crist et al., 2018; 
Fonseca and Torrens, 2018). Environmental factors also contribute to OUD (Lu et al., 2003; Badiani and 
Robinson, 2004; Scherbaum and Specka, 2008; Valentine and Fraser, 2008), and some environmental factors 
can affect the influence of genetic factors on predisposition to developing addiction (Ducci and Goldman, 
2012). The ability to identify a priori individuals at increased OUD risk would help greatly in prevention. For 
instance, using opioid analgesics with these individuals could be avoided or strictly monitored. 
 West Virginia is the epicenter of this opioid crisis, leading in opioid-related overdose deaths (Seth et al., 
2018). The state is also demographically homogenous (Gall et al., 2016)*, being predominantly whites (94%) of 
European Caucasian ancestry (2010 US Census Data; http://censusviewer.com/state/WV). These factors make 
West Virginia ideal for genetic studies aimed at curbing the opioid epidemic. West Virginia University’s 
Chestnut Ridge Center is home to a successful medication-assisted treatment program, known as the 
Comprehensive Opioid Addiction Treatment (COAT) clinic (Marshalek and Sullivan, 2010; Lander et al., 2013; 





whether there are single nucleotide polymorphisms (SNPs) more or less prevalent in WV persons with OUD 






















2.3 – METHODS 





60 volunteers, diagnosed with OUD using DSM-V criteria(Association, 2013), were recruited from WVU’s 
COAT clinic under IRB 1506733605. All participants were patients of the COAT clinic in Morgantown, West 
Virginia. The COAT clinic’s service area (and hence our research subject area) is geographically diverse, as it 
draws from the entire state.  
 
2.3.2 - Tissue Collection  
Consenting volunteers provided buccal swabs, which were placed in 15-ml conical centrifuge tubes (Corning) 
and stored at -80ºC. 
 
2.3.3 - Genomic DNA Extraction  
DNA was extracted using QIAamp DNA Mini Kits according to manufacturer’s protocol. Yield was assessed 
by measuring 260-nm absorbance of DNA extracts on a QIAxpert microfluidic reader. Purity was assessed by 
measuring 260-nm and 280-nm absorbance; all samples had a 260-nm/280-nm quotient greater than 1.8 units. 
 
2.3.4 - Genotyping 
Genotyping was performed using TaqMan (FisherSci #4351379) primer-probe sets for each SNP (Table 1) and 
Type-it Fast SNP Probe PCR Kits (Qiagen) according to manufacturer’s protocol. Samples were run on a Rotor-





2.3.5 - Statistical Analysis  
Allele frequencies were compared to those of 1006 individuals of European descent (1000 Genomes Project 





frequencies were compared to ExAc database(Song et al., 2016) of ~60,000 genomes. Statistical analyses for 
differences of SNP variant frequency between groups were performed using Pearson’s chi-square statistical test. 
The null hypothesis was that the allele frequencies from WV COAT clinic participants were the same as those 
from public databases. Therefore, p-value < 0.05 implies that the allele frequencies from WV COAT clinic 

















2.4 - RESULTS 
 A literature search for SNPs associated with OUD/SUD and/or related traits (e.g., anxiety) identified 
fourteen of known or suspected relevance to the biological actions of opioids (i.e., variations within genes 





2008), serotonin 5-HT2B receptor (Lin et al., 2004; Doly et al., 2008; Doly et al., 2009), and  -opioid receptor 
(Oertel et al., 2012; Beer et al., 2013; Carpentier et al., 2013; Gong et al., 2013; Haerian and Haerian, 2013; 
Kolesnikov et al., 2013; Manini et al., 2013; Song et al., 2013; Cajanus et al., 2014; Solak et al., 2014; Xu et al., 
2014; Adrian et al., 2015; Bartosova et al., 2015; Hancock et al., 2015; Laugsand et al., 2015; Olesen et al., 
2015; Pfeifer et al., 2015; Wachman et al., 2015; Woodcock et al., 2015; Matic et al., 2016; Schwantes-An et 
al., 2016; Choi et al., 2017; Gao et al., 2017; Levran et al., 2017)]; Regulators of G protein Signaling [RGS2, 
RGS17] (Smoller et al., 2008; Amstadter et al., 2009b; Amstadter et al., 2009a; Koenen et al., 2009; Zhang et 
al., 2012; Dunn et al., 2014; Stein et al., 2014; Hohoff et al., 2015); a nerve growth factor [brain-derived 
neurotrophic factor] (Egan et al., 2003; de Cid et al., 2008); a voltage-gated potassium channel 
[KCNC1](Nascimento and Andrade, 2016); and, a second messenger-regulated transcription factor [cyclic-
AMP responsive element binding protein-1] (Pal et al., 2014); Table 1). We isolated buccal swabs from 60 WV 
COAT clinic participants, prepared genomic DNA, and performed genotyping of the following SNPs. 
 
2.4.1 - OPRM1 rs9479757 (mu opioid receptor gene variant) (Beer et al., 2013; Xu et al., 2014; Olesen et al., 
2015)):  Xu et al. (Xu et al., 2014) identified rs9479757 as linked to heroin addiction severity among Han 
Chinese males; the G-to-A transition facilitates exon 2 skipping, leading to altered OPRM1 splice-variant 
mRNAs and encoded mu opioid receptor (MOR) isoforms. All sixty participants were heterozygous for OPRM1 
rs9479757; in contrast, the minor allele frequency in the general European population is only 0.097 (Table 1).  
 
2.4.2 - OPRM1 rs1799971 (mu opioid receptor gene variant) (Oertel et al., 2012; Carpentier et al., 2013; 
Gong et al., 2013; Haerian and Haerian, 2013; Kolesnikov et al., 2013; Manini et al., 2013; Song et al., 2013; 
Cajanus et al., 2014; Solak et al., 2014; Adrian et al., 2015; Bartosova et al., 2015; Hancock et al., 2015; 
Laugsand et al., 2015; Olesen et al., 2015; Pfeifer et al., 2015; Wachman et al., 2015; Woodcock et al., 2015; 
Matic et al., 2016; Schwantes-An et al., 2016; Choi et al., 2017; Gao et al., 2017; Levran et al., 2017)):  





OPRM1 rs1799971 minor allele (G) reported significantly more heroin use-related consequences and quit 
attempts, and were more likely to seek OUD treatment, than individuals homozygous for the ancestral A allele. 
Schwantes-An et al. (Schwantes-An et al., 2016), in a meta-analysis of ~28,000 Europeans, investigated non-
specific risk for SUD and compared cases dependent on any substance to controls not dependent on all assessed 
substances. The rs1799971 G allele showed a modest protective effect on general substance dependence 
(Schwantes-An et al., 2016). The rs1799971 G allele was significantly less frequent in WV COAT clinic 
participants than in the population at large, by a factor of ~2 (Table 1; 0.083 vs 0.162, p = 0.018).  
 
[Location of Table 1] 
 
2.4.3 - RGS2 rs4606 (Regulator of G protein Signaling-2 gene variant) (Smoller et al., 2008; Amstadter et 
al., 2009b; Amstadter et al., 2009a; Koenen et al., 2009; Dunn et al., 2014; Stein et al., 2014; Hohoff et al., 
2015)):  One of us (Oliveira-Dos-Santos et al., 2000) previously reported that loss of RGS2 in mice engenders 
heightened anxiety and diminished aggression. Subsequently, Smoller et al. (Smoller et al., 2008) found that 
RGS2 variations, including rs4606, were associated with introversion (a core personality trait in social anxiety 
disorder) (Smoller et al., 2008). Associations between the RGS2 SNP rs4606 and panic disorder (Hohoff et al., 
2015), suicidal ideation (Amstadter et al., 2009b), post-traumatic stress disorder (Amstadter et al., 2009a), and 
generalized anxiety disorder (Koenen et al., 2009) have also been reported. We found that rs4606 was more 
frequent in COAT clinic volunteers than in the general population by a factor of ~2 (Table 1; 0.533 vs 0.276, p 
< 0.001).  
 
2.4.4 - HTR2B rs6736017 (serotonin [5-HT] receptor-2B gene) (Lin et al., 2004; Doly et al., 2008; Doly et 
al., 2009) variant):  There are presently no published details on the HTR2B SNP rs6736017. However, HTR2B 
variations likely play a role in drug abuse. Doly et al. (Doly et al., 2008; Doly et al., 2009) showed that the 





(MDMA)-induced hyperlocomotion, serotonin and dopamine release, and conditioned place preference, the 
latter a rodent-based metric of reinforcing properties. Furthermore, Lin et al. (Lin et al., 2004) conducted a 
genome-scan identifying the human HTR2B gene as a candidate for drug abuse liability. The HTR2B SNP 
rs6736017 was markedly more frequent in COAT clinic participants than in the population at large, when 
comparing to the 60,000 genomes of the ExAc database (Table 1; 0.500 vs 0.0078, p < 0.01). 
 
 None of the other 10 SNPs investigated exhibited a significantly different frequency in the COAT clinic 







2.5 - DISCUSSION 
 We identified four SNPs present at different frequencies in persons with OUD compared with a 
demographically-matched general population. It is currently difficult to quantify the degree of significance of 
each of these altered frequencies on OUD in the COAT population. One reason for this difficulty is that many 
gene variants are likely to play an integrated role in predisposition to OUD, and these variants may have 
additive or synergistic effects; here, we have only interrogated 14 SNPs in 8 candidate genes. Also, possible 
gene x environment effects were not assessed in the present study. 
Two SNPs were in the OPRM1 gene encoding MOR -- the main molecular target for the euphoric 
effects of opioids, as well as for the therapeutic effects of buprenorphine (Marshalek and Sullivan, 2010; Zheng 
et al., 2017) and methadone in OUD treatment. Therefore, it is not surprising that OPRM1 variations would be 
associated with OUD. 
 We also identified an RGS2 variant associated with OUD. This finding is novel, but it is also not 
surprising. Opioids like oxycodone and buprenorphine generate neuronal signals by activating opioid-binding 
GPCRs, altering receptor conformation to cause nucleotide exchange (Siderovski and Willard, 2005) by the 
associated G protein heterotrimer (Galpha·GDP/Gbeta/Ggamma). GTP-loaded G-alpha then dissociates from 
the Gbeta/gamma heterodimer; both subunits become free to modulate enzymes that generate intracellular 
second messengers (e.g., cyclic AMP, calcium) or stimulate potassium channels, leading to neuronal membrane 
hyperpolarization and thus action potential inhibition. G-alpha proteins have intrinsic GTPase activity, leading 
to self-inactivation and reassociation with Gßɤsubunits (Siderovski and Willard, 2005). RGS proteins like RGS2 
greatly enhance the GTP hydrolysis rate of Gα subunits (Ingi et al., 1998; Siderovski and Willard, 2005; Kimple 
et al., 2009), thereby inhibiting GPCR signaling. Thus, one might indeed expect that a polymorphism in an RGS 
gene – encoding a negative regulator of GPCR signaling -- would be implicated in OUD. Moreover, RGS2 
function is particularly germane to multiple anxiety disorders (Smoller et al., 2008; Amstadter et al., 2009b; 
Amstadter et al., 2009a; Koenen et al., 2009; Dunn et al., 2014; Stein et al., 2014; Hohoff et al., 2015) that 





 HTR2B encodes the serotonin 5-HT2B receptor, implicated in the rewarding actions of MDMA (Doly et 
al., 2008; Doly et al., 2009) and cocaine (Doly et al., 2017), and thought to be involved in impulsivity 
(Bevilacqua et al., 2010) and resistance to antidepressants (Diaz et al., 2016), conditions that could predispose 
to OUD. Other polymorphisms in HTR2B have also been associated with vulnerability to illegal drug use(Lin et 
al., 2004). Therefore, our identification of a HTR2B polymorphism significantly more frequent in persons with 
OUD compared with a demographically-matched general population is not surprising. 
 There are several goals for identifying SNPs associated with OUD. One of these goals is to identify 
markers that, in genetic screens, could identify people at risk for developing OUD (e.g., before prescribing 
opioid analgesics). Another goal is to identify potential novel “druggable” targets for preventing and/or treating 
OUD. For instance, the published role of the 5-HT2B receptor in the actions of illicit drugs, coupled with our 
finding that rs6736017 is so frequent in OUD individuals, suggests that 5-HT2B receptor-active pharmaceuticals 
(of which many are already approved for human use) might have efficacy in preventing/treating OUD. Future 
studies with larger cohorts are required to validate our findings, both in West Virginia and in other, more 
demographically heterogeneous regions. Such studies should identify genes to interrogate in order to predict 




* Demographic homogeneity in West Virginia in no way reflects any heightened degree of consanguinity. 
Tincher (Tincher, 1980) examined 140 years' worth of marriage records in a remote four-county Appalachian 
region. While cousin marriage was found to occur in Appalachia, it was not conspicuously more prevalent than 




























2.6 – TABLES 
 
2.6.1 Table 1. Genetic markers and minor allele frequency (MAF) data obtained from public 






Table 1. Genetic markers and minor allele frequency (MAF) data obtained from public 
databases (1000 Genomes Project and/or ExAc) and WV COAT clinic patients (N = 60). 
Gene dbSNP ID Minor Allele 
TaqMan 
Probe 






OPRM1 rs9479757 A C_25472011_10 0.097 0.082 0.500 p < 0.001 
OPRM1 rs1799971 G C_8950074_1 0.162 0.185 0.083 p = 0.018 
RGS2 rs4606 G C_2498717_10 0.276 n.a. 0.533 p < 0.001 
HTR2B rs6736017 C C_25614588_20 n.a. 0.0078 0.500 p < 0.001 
OPRM1 rs2075572 G C_1691815_1 0.413 n.a. 0.483 p = 0.12 
RGS17 rs596359 T C_7830523_10 0.517 n.a. 0.467 p = 0.27 
DRD2 / 
ANKK1 rs1800497 A C_7486676_10 0.188 0.256 
0.217 
p = 0.41 
DRD2 rs1799978 C C_7486599_20 0.060 n.a. 0.075 p = 0.44 
BDNF rs6265 T C_11592758_10 0.197 0.194 0.167 p = 0.49 
KCNC1 rs60349741 C C_89088414_10 0.001 n.a. 0.000 
HTR2B rs77982984 A C_99996051_10 0.003 0.0012 0.000 
HTR2B rs78484969 C C_99996081_10 0.001  (N = 1030 Finns) n.a. 0.000 
HTR2B rs77570025 G C_99996068_10 0.006 0.002 0.000 
CREB1 rs35349697 A C_25636228_10 n.a. 0.000008 0.000 
 
* Minor allele frequency reported on N = 1006 Europeans via 1000 Genomes (except as otherwise noted); n.a. = 
not available. 
† Minor allele frequence reported on N ~ 60,000 people via ExAc database of the Broad Institute; n.a. = not 
available. 
‡ p-value, denoting significance of difference between MAFs, is derived by comparison between WV COAT clinic 
and European (if not, then ExAc) MAF using binomial test (null hypothesis is "no difference between WV COAT 
patients and Europeans"; alternative is "there is difference between WV COAT patients and Europeans") 
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3.1 - Abstract: 
mu opioid receptor (MOR)-targeting analgesics are efficacious pain treatments, but notorious for their abuse 
potential. In animal models, co-administration of traditional kappa opioid receptor (KOR)-targeting agonists 
with MOR-targeting analgesics can decrease reward and potentiate analgesia. However, traditional KOR-
targeting agonists are well known for inducing anti-therapeutic side effects (psychotomimesis, depression, 
anxiety, dysphoria). Recent data suggest that some functionally selective or “biased” KOR-targeting agonists 
might retain the therapeutic effects of KOR activation without inducing undesirable side effects. Nalfurafine, 
used safely in Japan since 2009 for uremic pruritus, is one such functionally selective KOR-targeting agonist. 
Here we quantify the bias of nalfurafine and several other KOR agonists against the unbiased reference standard 
U50,488 and show that nalfurafine demonstrates a significant G protein-signaling bias. While nalfurafine (0.015 
mg/kg) produces spinal analgesia (via a tail-immersion test) equivalent to 5 mg/kg of U50,488, it significantly 
enhances the analgesic effect of 5 mg/kg morphine in the hot plate assay. In addition, 0.015 mg/kg nalfurafine 
does not produce conditioned place aversion (CPA) yet retains the ability to reduce morphine-induced 
conditioned place preference (CPP) in C57BL/6J mice. Nalfurafine did produce robust inhibition of both 
spontaneous and morphine-stimulated locomotor behavior, however, suggesting a persistence of sedative effects 
when co-administered with morphine. Taken together, these findings suggest that G protein-biased KOR 
agonists may produce greater analgesic augmentation than unbiased agonists when combined with traditional 
opioid analgesics, while also reducing opioid-induced reward with less risk of dysphoria. Thus, adjuvant 
administration of G protein-biased KOR agonists may be beneficial in enhancing the therapeutic potential of 






3.2 - Introduction 
 Opioid use disorder (OUD) is an American health crisis (Manchikanti et al., 2012; Koh, 2015; Volkow and 
Collins, 2017). Use of prescription opioids, such as morphine and oxycodone, has contributed significantly to 
the OUD problem (Jones, 2013a). Morphine, the prototypical opioid analgesic, is a mainstay for treating 
moderate to severe pain as may occur post-operatively or in chronic illness. While prescription opioids are 
effective painkillers, there currently exists no facile way to use them for extended periods of time without the 
prospect of inducing tolerance, dependence and, in many cases, addiction. One plausible solution is to use 
morphine (and other MOR-targeting analgesics) in a way that increases its analgesic effects, thereby requiring 
lower doses (an approach known as “dose sparing”), or in a way that reduces addictive potential. In this vein, if 
the anti-nociceptive potential of MOR-targeting analgesics could be enhanced via an adjuvant that does not 
induce therapeutically limiting side effects, then their continued therapeutic use in treating pain could be 
extended.  
kappa opioid receptor (KOR)-targeting agonists, when given with MOR-targeting analgesics, not only 
produce additive analgesia (Sutters et al., 1990; Negus et al., 2008b; Briggs and Rech, 2009), reduced tolerance 
(He and Lee, 1997; Khotib et al., 2004), and reduced respiratory depression (Verborgh et al., 1997) but can also 
reduce the rewarding properties of MOR-targeting analgesics (Kuzmin et al., 1997; Tsuji et al., 2001; Tao et al., 
2006). However, clinical use of some KOR agonists, such as ketocyclazocine (Kumor et al., 1986) or salvinorin 
A (MacLean et al., 2013), has largely failed due to poor tolerability. In rodents, traditional KOR agonists 
produce anxiety- and depressive-like behaviors (Carlezon et al., 2006; Bruchas et al., 2009; Ehrich et al., 
2015a), as well as locomotor suppression (Kunihara et al., 1993; Narita et al., 1993; Ehrich et al., 2015a; Brust 
et al., 2016b). In humans, the highly selective KOR agonist salvinorin A produces similar therapeutically 
limiting effects (MacLean et al., 2013; Maqueda et al., 2015; Johnson et al., 2016).  
Thus, it is not surprising that initial enthusiasm for KOR agonists as adjuvants to MOR-targeting analgesics 
was reduced by early preclinical and clinical findings using single applications of mixed MOR/KOR agonists. 





morphine and enhanced morphine-induced analgesia (Tao et al., 2006), human studies demonstrated dose-
dependent increases in dysphoria (Jasinski and Mansky, 1972; Preston et al., 1989a; Walsh and Babalonis, 
2017). Similarly, pentazocine and butorphanol also induce classic dysphoric effects of traditional KOR-
targeting agonists in humans, especially at higher doses (Preston et al., 1987; Zacny et al., 1994; Greenwald and 
Stitzer, 1998; Walsh et al., 2008; Walsh and Babalonis, 2017), limiting their therapeutic potential. 
Recent efforts to develop non-addictive opioids however, have renewed interest in KOR ligands with 
specific emphasis on developing functionally selective (or “biased”) KOR agonists (Urban et al., 2007; 
Rankovic et al., 2016). G protein-biased KOR agonists demonstrate reduced potencies for signaling through the 
GRK/b-arrestin pathway (Bohn and Aube, 2017). While G protein-dependent signaling through KOR is well 
established as producing the primary therapeutic outcome of analgesia (Chavkin, 2011; Brust et al., 2016b; 
Schattauer et al., 2017), the role of GRK/b-arrestin signaling in producing dysphoria downstream of KOR 
activation is less clear. Some have shown that aversive behavior toward KOR agonists requires GRK3 (and p38 
MAPK) activation (Bruchas et al., 2007b; Chavkin et al., 2014; Ehrich et al., 2015a), while others have 
observed little effect of Arrb2 ( -arrestin-2) genetic ablation on the aversion produced by a variety of KOR 
agonists (White et al., 2015). Recent work with triazole 1.1 (Brust et al., 2016b), however, and nalfurafine (Liu 
et al., 2018) suggests that these G protein-biased KOR agonists may lack dysphoric effects at doses that produce 
analgesia, supporting the role of b-arrestin signaling in the dysphoric effects of traditional KOR agonists. G 
protein-biased KOR agonists may, thus, present a strategy for reducing the rewarding properties of MOR-
targeting analgesics while avoiding the pitfalls of traditional KOR agonists. This notion is supported by a recent 
preclinical study in rats (Townsend et al., 2017b) showing that nalfurafine reduces intravenous self-
administration of the MOR-targeting analgesic oxycodone while also potentiating its analgesic effect. 
Nalfurafine is a G protein functionally selective KOR-targeting agonist with high translational potential 
given its safe usage in Japan since 2009 to treat uremic pruritis and, importantly, does not produce 





potentiating the analgesic effect and reducing the rewarding properties and of the MOR-targeting analgesic 







3.3 - Methods:  
3.3.1 - Animal Subjects 
All experiments were conducted using male and female C57BL/6J mice (RRID: IMSR_JAX:000664) 
between 8-14 weeks of age and 17-35 g; the sexes were used in similar proportions across all experiments. 
Original breeding pairs were obtained from The Jackson Laboratory (Bar Harbor, ME). All procedures were 
carried out in accordance with the National Research Council’s Guide to the Care and Use of Laboratory 
Animals (Eighth Edition), and were approved by West Virginia University’s Institutional Animal Care and Use 
Committee. 
3.3.2 - Study Design 
Mice were randomly assigned to treatment conditions, after being balanced for sex. Mice were 
acclimated to the test room for at least 30 min prior to any study. All mice were used for a single experimental 
assay. Sample size for each experiment was determined by power analysis using effect sizes derived from 
literature, power value of 0.8, and an alpha value of 0.05. All experiments were done by personnel who were 
blinded to treatment conditions. 
3.3.3 - Drugs 
(±) U50,488, GR 89696, and ICI 199,441 were all purchased from Tocris Biosciences (Minneapolis, MN). 
Nalfurafine hydrochloride was purchased from Medchem Express (Monmouth Junction, NJ). Morphine sulfate 
salt pentahydrate was purchased from Sigma Aldrich (St. Louis, MO). Salvinorin A, ethoxymethyl ether Sal B 
(EOM Sal B), and triazole 1.1 were prepared as previously described (Zhou et al., 2013; Ewald et al., 2017a). 
All drugs were dissolved in 100% DMSO and diluted in saline to the desired concentration (no DMSO 
concentration exceeded 5% v/v final). In drug combination experiments, nalfurafine was injected 
subcutaneously (sc) as described in the limited literature available regarding this compound’s use in mice 
(Endoh et al., 1999; Tsuji et al., 2001; Liu et al., 2018), while U50,488 and morphine were delivered by 
intraperitoneal (ip) injection as commonly described (Rada et al., 1996; McLaughlin et al., 2006; Koo et al., 





and U50,488 were chosen based upon the place preference data in the literature (Tsuji et al., 2001; Land et al., 
2009b; Ehrich et al., 2015b). Dose range for morphine was chosen to produce consistent place preference while 
allowing for high sensitivity to detect potentiation in the hot plate assay of analgesia (Mueller et al., 2002; 
Raehal and Bohn, 2011)  
3.3.4 - Measurement of Signaling Bias 
Quantification of G protein signaling dependent changes in intracellular cyclic AMP (cAMP) levels was 
conducted using a GloSensor luciferase-based assay in HEK293T cells transiently transfected with 5 µg of 
KOR expression vector DNA (3xHA-hKOR; www.cDNA.org) and 5 µg of pGloSensor-22F cAMP biosensor 
expression vector DNA (Promega, Madison, WI). Quantification of b-arrestin recruitment was conducted using 
the luciferase-based TANGO assay (Barnea et al., 2008; Allen et al., 2011) in HTLA cells (generously provided 
by Dr. Gilad Barnea) transiently transfected with 5 µg of KOR-V2-TEV-tTA expression vector DNA (Addgene 
plasmid #66462 donated by Dr. Bryan Roth). The appropriate masses of expression vector DNAs transfected 
was empirically determined prior to acquisition of the data contained herein. Transfections were performed in 
10-cm dishes using the calcium phosphate-based method (Jordan et al., 1996). Culture media was replaced 16 
hrs after transfection, and cells then plated on 96-well plates approximately 24 hrs after transfection. All cells 
were serum-starved with 1% dialyzed serum-containing medium for 8-16 hrs before assaying. For assays of 
cAMP inhibition, medium was replaced with GloSesnor detection reagent dissolved in HEPES (20 mM)-
buffered Hank’s balanced saline solution, and cells were incubated for 2 hrs at room temperature. KOR-
selective agonists were applied for 15 min prior to a 15-min stimulation with 100 nM isoproterenol (to induce 
endogenous b-adrenergic receptor-mediated and Gas-dependent production of cAMP) and subsequent 
quantification of luminescence. For TANGO assays of b-arrestin recruitment, drug stimulation was performed 
overnight in 1% dialyzed serum-containing medium. Medium was removed the following morning, the cells 
lysed with BrightGlo reagent (Promega), and luminescence quantified using a FlexStation 3 multi-mode plate 





3.3.5 - Calculation of Bias Factor 
Bias factors were calculated using the method previously described (Kenakin, 2017). Briefly, 
Log(Emax/EC50) values for both GloSensor and TANGO assays were separately generated for each ligand using 
potency (EC50) and maximal efficacy (Emax) values obtained from these assays. 𝚫Log(Emax/EC50) was calculated 
in each assay as the difference in Log(Emax/EC50) for each ligand from the reference ligand (the unbiased KOR 
agonist U50,488). 𝚫𝚫Log(Emax/EC50) was then calculated as the difference in 𝚫Log(Emax/EC50) between 
GloSensor and TANGO assays for each ligand. The 95% confidence interval (CI) for each bias factor was 
calculated using the Emax and EC50 values generated in individual experiments for each ligand in each assay. 
3.3.6 - Warm Water Tail Withdrawal 
The warm water tail withdrawal test was conducted as described previously (Schattauer et al., 2017). 
Briefly, mice were gently wrapped in cloth before immersing the distal 2 cm of the tail in 55°C water and 
recording the latency for the mouse to withdraw its tail from the water. Baseline latencies were recorded 30 min 
after administration of vehicle. Mice were then injected with drug and latencies were recorded after 30 min. A 
maximum cutoff of 10 s was used to avoid tissue damage. Data are presented as latency to tail-withdrawal in 
seconds as well as percent maximum possible effect (%MPE) following the equation: %MPE = (latency - 
baseline) / (10 sec - baseline) * 100%).   
3.3.7 - Hot Plate Analgesia Test 
To assess integrated pain perception, the hot plate test of nociception was performed as described previously 
(Raehal and Bohn, 2011) with minor modification. Nociceptive latency after vehicle injection was measured 
on Day 1. On Day 2, mice were injected with drug and response latencies were measured after 30 min. 
Individual mice were placed onto a 53ºC hot plate (IITC Life Science Inc.; Woodland Hills, CA) inside of a 
clear, open-bottom acrylic cylinder. A maximum cutoff of 30 s was used to avoid tissue damage. Time until 
the first nociceptive sign (i.e., licking of the hind paw, flicking of the hind paw, or jumping) was recorded 





(latency - baseline) / (30 sec - baseline) * 100%). Data were analyzed by one way ANOVA with a Tukey’s 
post hoc test, using Prism 7 software. 
3.3.8 - Locomotion 
Locomotor activity was assessed using a 16 X 16 open-field infrared photobeam activity system (PAS) from 
San Diego Instruments (San Diego, CA), as described previously (Gross et al., 2018). Briefly, locomotion was 
quantified as total beam breaks in the x and y coordinates in five minute bins. Spontaneous locomotion was 
assessed by administering drug or vehicle immediately before placing the mouse in the locomotor chamber for 
60 min. Morphine-induced locomotion was assessed in a three-day procedure. On Day 1, mice were habituated 
to the locomotor chamber for 60 min. On Day 2, mice were habituated to the locomotor chamber for 30 min 
before receiving an injection of vehicle and returning to the chamber for an additional 60 min. On Day 3, mice 
were habituated to the locomotor chamber for 30 min before receiving an injection of either morphine with 
vehicle or morphine with KOR agonist, and returning to the chamber for an additional 60 min. Data plotted over 
time were normalized to the average vehicle locomotion in the first 5 minute bin for novelty induced 
locomotion and to the average locomotion of each subject during the 30 min prior to injection for morphine 
suppressed locomotion. For total novelty locomotion, data are normalized to the average total locomotor 
activity of the vehicle condition over the full 60 minute trial. For total morphine stimulated locomotion, data are 
normalized to the average total locomotor activity during the 60 minutes post vehicle injection on day 2.        
3.3.9 - Conditioned Place Preference/Aversion 
CPP and CPA studies were conducted as described previously (Redila and Chavkin, 2008) with the 
following modifications. A two-chambered place preference apparatus with differential floor grating in the 
white and black chambers was used. Baseline preference was established on Day 1 by allowing the mouse free 
access to both chambers for 30 min (for U50,488 studies) or 50 min (for nalfurafine studies, given prior 
evidence of time-of-effect for this compound (Tsuji et al., 2001)) and recording the amount of time spent in 
each chamber. The conditioning phase occurred on days 2 and 3 in 30 min (U50,488) or 50 min (nalfurafine) 





sessions. For CPP, drug was administered in the least-preferred chamber to override the initial preference of the 
mouse. Drug was administered in the most-preferred chamber for CPA. Preference was assessed on Day 4 by 
allowing the mouse free access to both chambers for 30 min (U50,488) or 50 (nalfurafine) min, and recording 
the amount of time spent in each chamber. ANY-maze video tracking software (Stoelting Co., Wood Dale, IL) 
was used to track movement and time spent in each chamber. Data are presented as the difference in time spent 
in the drug-paired chamber for each mouse. Data were analyzed by two-way ANOVA with Dunnett’s post hoc 
test to compare to vehicle controls and Sidak’s post hoc test to compare across genotypes, each run using Prism 














3.4 - Results 






Before launching our assessment of the efficacy of G protein-biased KOR agonists in reducing the addictive 
properties of morphine, we characterized the signaling properties of a variety of KOR-specific compounds to 
identify a suitable biased KOR agonist. Utilizing a GloSensor-based cAMP assay to determine G protein 
signaling, and the TANGO assay to determine b-arrestin recruitment, we identified EOM-salvinorin B (Bias 
Factor = 15.26, +95%CI = 29.95, -95%CI = 7.78) and nalfurafine (Bias Factor = 7.73, +95%CI = 15.16,                     
-95%CI = 3.94) as strongly G protein-biased KOR agonists (Figure 1), the latter consistent with prior findings 
(Schattauer et al., 2017). As nalfurafine has been used successfully for nearly a decade in Japanese patients for 
the treatment of uremic pruritus (Ueno et al., 2013; Inui, 2015), we chose it as our biased KOR agonist given its 
greater translational potential as a viable pharmaceutical adjuvant. 
3.4.2 - Spinal anti-nociception by nalfurafine 
 To establish the level of analgesia to be expected from these doses of nalfurafine, we assessed their 
abilities in the mouse tail immersion test (relative to the unbiased KOR agonist U50,488) to produce spinal anti-
nociception, an outcome of KOR agonism known to be G protein-dependent. Tail withdrawal latencies were 
analyzed by one-way ANOVA: F(6,152)=29.97, p<0.0001. All doses of nalfurafine produced significant 
increases in withdrawal latency compared to vehicle (Figure 2; p<0.0001 for each; Dunnett’s post hoc test). 
Administration of 1.25 mg/kg and 5 mg/kg U50,488 also increased tail withdrawal latency compared to vehicle 
(Figure 4; p<0.001 and P<0.0001 respectively), while no significant difference was observed between 2.5 
mg/kg U50,488 and vehicle (Holm-sidak post hoc test, p>0.05), though 5 mg/kg was significantly higher than 
2.5 mg/kg U50,488 (Holm-sidak post hoc test, p<0.05). No significant difference was observed between 1.25 
mg/kg and 5 mg/kg U50,488 (Holm-sidak post hoc test,  (p>0.05). Both 0.015 mg/kg and 0.03 mg/kg doses of 
nalfurafine elicited comparable anti-nociception to 5 mg/kg U50,488 (Holm-Sidak post hoc test, p=0.613 for 
both). 
3.4.3 - Enhancement of morphine-induced supraspinal analgesia by nalfurafine co-administration 
 To assess the effect of KOR agonism on the integrated nociceptive response, we assessed the effect of 





administration of U50,488 was analyzed by one-way ANOVA: F(6,57)=4.798, p=0.0005. Nociceptive latency 
with administration of nalfurafine was also analyzed by one-way ANOVA: F(6,68)=31.80, p<0.0001. We found 
that no dose of U50,488 nor nalfurafine produced a significant analgesic response on its own in the hot plate 
assay of nociception (Figure 5; Sidak’s post hoc test, p > 0.05). Co-administration of 2.5 mg/kg U50,488 with 5 
mg/kg morphine significantly increased analgesia compared to U50,488 alone (Holm-Sidak’s post hoc test, p < 
0.01; Figure 5A), but this level of analgesia was not significantly different from 5 mg/kg morphine alone 
(Holm-Sidak’s post hoc test, p > 0.05; Figure 5A). 
 Co-administration of all doses of nalfurafine tested with 5 mg/kg morphine significantly increased analgesia 
compared to nalfurafine alone (Holm-Sidak’s post hoc test, p < 0.0001; Figure 5B) and 5 mg/kg morphine alone 
(Holm-Sidak’s post hoc test, p<0.0001 for 0.015 and 0.06 mg/kg nalfurafine co-admin; p<0.001 for 0.03 mg/kg 
nalfurafine co-admin, Figure 5B) .  
3.4.4 - Locomotor suppression by nalfurafine administration and co-administration 
 Open-field locomotion represents a behavioral outcome of mesolimbic dopamine release and is increased by 
movement of mice into a novel environment, as well as by administration of many drugs of abuse to mice 
(Bardo et al., 1990; Sellings and Clarke, 2003; Bromberg-Martin et al., 2010; Fields and Margolis, 2015). 
Traditional KOR agonists suppress both spontaneous as well as opioid analgesic-induced locomotion (Narita et 
al., 1993; Chefer et al., 2005; Bruijnzeel, 2009). Suppression of total novelty-induced locomotion was analyzed 
by one-way ANOVA: F(6,104)=18.01; p<0.0001. We found that total spontaneous locomotion was 
significantly reduced upon administration of 2.5 and 5 mg/kg U50,488 (p<0.05 and p<0.01 respectively), as 
well as 0.015, 0.03 and 0.06 mg/kg nalfurafine (p<0.001, and p<0.0001 respectively) compared to vehicle 
(Dunnett’s post hoc test; Figure 6A and inset). The dose of 0.06 mg/kg nalfurafine elicited a significantly 
greater reduction in spontaneous locomotion, as compared to 1.25, 2.5 or 5 mg/kg U50,488 (p<0.0001, p<0.001, 
and p<0.0001 respectively), or 0.015 and 0.03 mg/kg nalfurafine (p<0.05, p<0.01 respectively); Tukey’s post 





U50,488 (Tukey’s post hoc test, p≥0.4698), nor between 5 mg/kg U50,488 and 0.015 or 0.03 mg/kg nalfurafine 
(Tukey’s post hoc test, p=0.9336 and p=0.9480, respectively). 
 Modulation of total morphine-stimulated locomotion by U50,488 was analyzed by one-way ANOVA: 
F(3,32)=6.142, p=0.0020. Modulation by nalfurafine was also analyzed by one-way ANOVA: F(3,27)=30.11, 
p<0.0001. Suppression of locomotion was seen with co-administration of 5 mg/kg morphine with 5 mg/kg 
U50,488 (Dunnett’s post hoc test, p<0.01; Figure 6D and inset), as well as with all doses of nalfurafine 
(Dunnett’s post hoc test, p<0.0001; Figure 6E and inset). 
3.4.5 - Dose-dependent conditioned place aversion by nalfurafine 
 To help assess the level of anti-therapeutic liability presented by nalfurafine, we measured its ability to 
produce conditioned place aversion in mice (Figure 3), a behavior linked to b-arrestin signaling downstream of 
KOR activation (Bruchas et al., 2007b; Ehrich et al., 2015a) and a therapeutically-limiting effect of traditional 
KOR agonists like U50,488 (Jasinski and Mansky, 1972; Preston and Bigelow, 1993; Siebert, 1994; Greenwald 
and Stitzer, 1998). U50,488-induced CPA was analyzed by two-way ANOVA: test day effect, F(1,39)=20.41, 
p<0.0001; treatment effect, F(3,39)=8.940, p=0.0001; interaction effect, F(3,39)=4.684,  p=0.0072; subject 
effect, F(39,39)=0.8332, p=0.7143. Nalfurafine-induced CPA was also analyzed by two-way ANOVA: test day 
effect, F(1,50)=13.04, p=0.0007; treatment effect, F(3,50)=2.302, p=0.0884; interaction effect, F(3,50)=2.572, 
p=0.0645; subjects effect, F(50,50)=0.9840, p=0.5227 We found that all doses of U50,488 produced aversion 
compared to vehicle (Dunnett’s post hoc test, 1.25 mg/kg = p< 0.05, 2.5 mg/kg = p<0.001, and 5 mg/kg = 
p<0.01 Figure 3A) with no significant difference between doses (Holm-Sidak post hoc test, p>0.05) while only 
the 0.03 mg/kg dose of nalfurafine produced statistically significant aversion compared to vehicle (Dunnett’s 
post hoc test, p<0.01; Figure 3B) with no significant difference between doses (Holm-sidak post hoc test, 
p>0.05).  
3.4.6 - Modulation of morphine-induced conditioned place preference by nalfurafine 
 As unbiased KOR agonists have been observed, when co-administered, to reduce the rewarding properties 





of nalfurafine co-administration in mice to reduce the conditioned place preference produced by morphine. 
U50,488 results were analyzed by two-way ANOVA: test day effect, F(1,78)=218.2, p<0.0001; treatment 
effect, F(3,78)=0.8699, p=0.4604; interaction effect, F(3,78)=3.482, p=0.0197; subject effect, F(78,78)=1.032, 
p=0.4441. Morphine alone (5 mg/kg) produced place preference compared to preconditioning (Sidak post hoc 
test, p<0.0001; Figure 2). U50,488 co-administration (at 1.25 mg/kg and 5 mg/kg) reduced preference for 
morphine (Dunnett post hoc test, p < 0.05; Figure 2A), though there was no significant difference between 
doses (Holm-Sidak post hoc test, p>0.05). Nalfurafine results were also analyzed by two-way ANOVA: test day 
effect, F(1,85)=169, p<0.0001; treatment effect, F(3,85)=5.049, p=0.0029; interaction effect, F(3,85)=1.209, 
p=0.3116; subjects effect, F(85,85)=0.9096, p=0.6683. Nalfurafine co-administration showed no effect on 
morphine-induced preference at 0.03 mg/kg, but produced a significant reduction in morphine preference at 
0.015 mg/kg and 0.06 mg/kg, with 0.06 mg/kg being significantly different from 0.03 mg/kg nalfurafine co-







3.5 - Discussion 
 Our results support nalfurafine as a G protein-biased KOR agonist that can beneficially modulate both the 
analgesic and rewarding properties of morphine in vivo upon co-administration; however, nalfurafine also 
produced aversion and locomotor suppression in mice. KOR agonists reduce reward associated with drugs of 
abuse (Lindholm et al., 2001; Morani et al., 2009a; Townsend et al., 2017b); however, their clinical viability has 
been hampered by dysphoria in patients (Jasinski and Mansky, 1972; Preston and Bigelow, 1993; Siebert, 1994; 





downstream of b-arrestin mobilization (Bruchas et al., 2007b; Ehrich et al., 2015a) and, thus, G protein-biased 
KOR agonists may lack dysphoric properties (Brust et al., 2016b; Liu et al., 2018). Our data demonstrate that 
while nalfurafine retains the ability to produce conditioned place aversion, the augmentation of morphine’s 
analgesic effect persists at lower doses, providing evidence that G protein-biased KOR agonists may have 
increased clinical utility as dose-sparing agents compared to unbiased KOR agonists. Proper dose combinations 
may provide augmented analgesia while avoiding dysphoria and minimizing sedation. 
 Initial in vitro screening identified both nalfurafine and EOM Sal-B as potent and significantly G-protein 
biased KOR agonists. We chose to focus our initial efforts on nalfurafine due to its greater translational 
potential, being used safely in Japan since 2009 (Inui, 2015). 
We first assessed spinal nociception utilizing the warm water tail withdrawal assay. As previous studies 
demonstrate that KOR agonist-induced increases in withdrawal latency are G protein-signaling dependent 
(Hernandez et al., 1995; Berg et al., 2011; White et al., 2015; Abraham et al., 2018), this assay also allowed for 
comparison of in vivo G protein-signaling between nalfurafine and U50 at the selected doses. A dose of 5 mg/kg 
U50,488 produced analgesia that was statistically equivalent to both 0.015 and 0.03 mg/kg nalfurafine. This 
finding suggests that KOR-mediated G protein signaling is equivalent in vivo between the higher dose of 
U50,488 and the lowest tested doses of nalfurafine. 
As the supraspinal analgesia produced by MOR-targeting analgesics represents a major factor in their 
clinical success (Kanjhan, 1995; Jensen, 1997), we next assessed the effect of co-administration in a non-
reflexive assay of nociception. While no significant analgesic effect of U50,488 or nalfurafine alone was 
observed in the hot plate assay compared to morphine alone, there was a significant effect of nalfurafine upon 
co-administration with morphine (Figure 5B). This increased analgesic effect was not seen with co-
administration of U50,488. One potential explanation of this effect is that the locomotor-suppressing property of 
nalfurafine (Figure 6) hinders the expression of nociceptive behaviors (e.g., jumping or paw flicking/licking), 
thereby falsely increasing nociceptive latency measurements. In the assay of morphine stimulated locomotion 





yet only nalfurafine co-administration is seen to elicit augmented analgesia (Figure 5B). These findings make a 
locomotor confound to nociception measurement less likely. In this light, future studies are planned to 
investigate the effects of nalfurafine and MOR agonist co-administration on pain-suppressed behaviors to 
further investigate the potential confound and better characterize the analgesic interactions of these two drugs. 
As 5 mg/kg U50,488 and 0.15 mg/kg nalfurafine produced equivalent increases in tail withdrawal latencies, 
the increased analgesic effect seen in the hot plate with co-administration of nalfurafine may indicate a 
beneficial supra-spinal or spinal interaction between morphine and nalfurafine downstream of G protein-
signaling at KOR. Early work with site specific administration of MOR and KOR agonists demonstrate 
analgesic synergism when given intrathecally (i.t.) but not intracerebroventricularly (i.c.v.) (Ren et al., 1985; 
Sutters et al., 1990; Miaskowski et al., 1992; Miaskowski et al., 1993), suggesting that while KOR-dependent 
spinal analgesia is equivalent between 0.015 nalfurafine and 5 mg/kg U50,488, the biased signaling profile of 
nalfurafine produces a greater analgesic interaction between MOR and KOR signaling. 
To assess the potential clinical viability of this co-administration paradigm, we evaluated these doses of 
nalfurafine and U50,488 for sedation and dysphoria. In the present study, significant reductions in spontaneous 
locomotion were seen with all KOR agonists tested except 1.25 mg/kg U50,488. This observation of sedation 
persisted when these KOR agonists were co-administered with morphine. However, post-marketing surveillance 
of nalfurafine reports a low incidence of somnolence (1%), at doses safe and efficacious in human patients 
(Kozono et al., 2018), suggesting that sedation may not necessarily prove to be an anti-therapeutic effect of 
nalfurafine co-administration with a MOR-targeting analgesic.   
To assess dysphoria, we utilized the CPA assay. Aversion to KOR agonists has been linked to signaling 
downstream of ß-arrestin (Bruchas et al., 2007b; Ehrich et al., 2015a) and previous work has demonstrated a 
lack of CPA to nalfurafine (Tsuji et al., 2001; Liu et al., 2018). In our CPA assays with nalfurafine, only 0.03 
mg/kg produced significant aversion, as compared to U50,488 which produced significant aversion at all doses 





previous study (Robles et al., 2014) and could reflect the appearance of cognitive deficits (Castellano et al., 
1988; Carey et al., 2009). 
Of note is the finding that 0.03 mg/kg nalfurafine produced significant aversion. This result is supported by 
recent work demonstrating that the G protein biased KOR agonist RB-64 produces aversion in both wild-type 
and b-arrestin-2 knockout mice (in addition to the unbiased KOR agonists U69,593 and salvinorin A (White et 
al., 2015)), suggesting that aversion to KOR agonists may be produced in part through mechanisms independent 
of b-arrestin-dependent signaling. G protein-biased KOR agonists might thus retain the ability to produce 
aversion, though less potently than unbiased agonists. 
  Lastly, KOR agonists are known to reduce the rewarding properties of a variety of drugs of abuse 
(Kuzmin et al., 1997; Lindholm et al., 2001; Tsuji et al., 2001; Tao et al., 2006; Morani et al., 2009a; Ewald et 
al., 2017a; Townsend et al., 2017a), presenting a second possible benefit of combination therapy. Using the CPP 
assay, we found that nalfurafine reduces the rewarding properties of 5 mg/kg morphine at 0.015 and 0.06 
mg/kg, while 0.03 mg/kg produced no effect on morphine place preference. Though a dose of 0.03 mg/kg 
reduced morphine CPP in a previous study, a potential source of this difference could be our use of inbred 
C57BL/6J mice, as opposed to the use of outbred ddY male mice (Tsuji et al., 2001). Indeed, strain differences 
in response to KOR agonists, as well as to psychostimulant drugs of abuse, have previously been demonstrated 
(e.g., (Castellano et al., 1988; Mouri et al., 2012)).   
Administration of U50,488 displayed a similar pattern, with doses of 1.25 and 5 mg/kg suppressing 
morphine place preference, while 2.5 mg/kg was not a statistically significant suppression. Similar to results 
seen in CPA, the reduction in morphine induced CPP at the highest doses of each KOR agonist may be 
explained in part by cognitive disruption preventing the effective pairing of stimulus with context. Effects seen 
with the low and middle dose of each drug were opposite of expected. Interestingly, the doses of both drugs 
producing the greatest level of aversion produced the least suppression of morphine induced CPP. While 
extensive work focuses on KOR agonists effects on cocaine CPP (Suzuki et al., 1992; Redila and Chavkin, 





any using multiple doses of KOR agonist. Outside of the work by Tsuji et al. referenced earlier, a related lab 
demonstrated that 1 mg/kg U50,488 reduced CPP to 5 mg/kg morphine, though other doses of U50,488 were 
not assessed (Masahiko et al., 1993). A drawback of the CPP procedure is its relatively low sensitivity to dose 
magnitude (Napier et al., 2013), making dose-response relationships difficult to properly establish, however the 
effects reported here indicate an interaction between the dose of KOR agonist and the rewarding properties of 
morphine. As pretreatment with U50,488 has been shown to increase CPP to cocaine, it is possible that 
differences in the timing of KOR agonist effects at different doses in relation to the rewarding effects of 
morphine play a role in the observed response pattern. A more detailed interrogation of the effects seen in CPP 
with an expanded dose range and varied pretreatment intervals could aid in determining the pharmacodynamic 
and pharmacokinetic factors involved.  
Taken together, these data suggest that G protein-biased KOR agonists may be effective dose-sparing 
adjuvants for traditional MOR-targeting analgesics. As all doses of nalfurafine provided similar augmentation 
of morphine’s analgesic effect, low doses may provide adequate analgesic synergism while avoiding dysphoria 
and sedation. Nalfurafine is used in the treatment of uremic pruritis at doses that produce low rates of sedation, 
insomnia, constipation, psychosis and other common KOR related side-effects (Kozono et al., 2018). The anti-
pruritic dose in rodents extends as low as 5 µg/kg (Liu et al., 2018). As a dose of 0.015 mg/kg effectively 
reduces morphine CPP without significant aversion, it is possible that doses already used in human subjects to 
treat pruritis may produce the benefits of co-administration described herein while avoiding significant anti-
therapeutic effects. Though the signaling pathways involved in both the intended and unintended effects of 
KOR agonism requires further investigation, the reduced side-effect profile of nalfurafine as compared with 
unbiased KOR agonists suggests that G protein-biased KOR agonists may be clinically relevant adjuvants for 
opioid-based pain therapies, particularly in acute in-patient settings. Additional studies are planned to 
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3.6 – Figures 
 








Figure 1. Nalfurafine is a potent G protein biased KOR agonist. Comparison of G protein and b-arrestin 
signaling outcomes with a variety of KOR ligands (at indicated concentrations) as compared to the reference 
standard U50,488. (A) G protein signaling was assessed with a GloSensor assay of cyclic AMP inhibition. (B) 
b-arrestin recruitment to the activated KOR was assessed via the TANGO assay. (C,D) Results from GloSensor 
and TANGO assays used to calculate Bias Factors for each compound from observed maximal efficacy (Emax or 
“Max”) and potency (EC50) values.   Log(Max/EC50) values, with their 95% confidence intervals (CIs), are 
plotted in panel D for each compound to indicate relative bias towards G protein signaling. All compounds were 
































Figure 2. Spinal anti-nociception in C57BL/6J mice is equivalent at 5 mg/kg U50,488 and 0.03 mg/kg 
nalfurafine. Mice were treated with vehicle 30 min prior to establishing baseline latencies, then treated 
with indicated doses of nalfurafine or U50,488 30 min prior to testing. Data were analyzed by one- way 
ANOVA with Dunnett’s multiple comparison post hoc test to assess for differences from the pooled 
vehicle. Holm-sidak multiple comparison post hoc test was used to assess for differences between 
treatment groups (n= 10-18 for all treatment conditions; ns, non-significant; *, p<0.05; **, p < 0.01; ****, 


































Figure 3. Nalfurafine potentiates morphine-induced supraspinal analgesia in C57BL/6J mice. Mice 
were treated with indicated doses of morphine, nalfurafine, U50,488, or a combination of morphine (5 
mg/kg) with either nalfurafine or U50,488. Latency to nociceptive response was recorded and compared to 
the response to saline [%MPE = (test response - baseline)/(30 sec - baseline); thus, 100% MPE = 30 sec 
with no sign of nociception]. Data were analyzed by one- way ANOVA with Dunnett’ multiple 
comparison post hoc test to assess differences from 5 mg/kg Morphine and Holm-sidak multiple 
comparison post hoc test to assess differences between treatment groups. ns, non-significant; *, p < 0.05; 
**, p < 0.01; ***, p<0.001; **** or ####, p < 0.0001. A. 5 mg/kg morphine n=16; all other conditions 













Figure 4. Nalfurafine treatment suppresses both spontaneous and morphine-induced locomotion. 
Assessment of open field locomotion elicited by environmental novelty or morphine administration.  
(A) For assessment of spontaneous locomotion, mice were administered vehicle or indicated single drug and 
immediately placed into the open field chamber for 60 min. (B, C) For assessment of morphine-induced 
locomotion, mice were again habituated to the chamber for 30 min (on Day 3) before receiving 5 mg/kg 
morphine with vehicle, or 5 mg/kg morphine with either 1.25, 2.5 or 5 mg/kg U50,488 (panel B), or 5 mg/kg 
morphine with either 0.015, 0.03 or 0.06 mg/kg nalfurafine (panel C) and assessed for locomotor behavior for 
an additional 60 min. Locomotion was measured by number of IR-beam breaks per 1 min. Data are presented as 
percent of pooled vehicle locomotion over the 60 min post injection for suppression of novelty induced 
locomotion. Total locomotion data were analyzed by one-way ANOVA with a Dunnett’s post hoc analysis to 
compare treatment groups to the vehicle alone or vehicle + morphine condition and Tukey’s post hoc analysis to 
assess difference between treatment conditions for novelty locomotion. Novelty locomotion n: vehicle= 41, all 
other conditions 7-16. Morphine suppressed locomotion n= 7-11 for all conditions. *, p<0.05; **, p<0.01; ***, 
p<0.001; ****, p<0.0001. ##, p<0.01; #, p<0.05. 
 
 
3.6.5 Nalfurafine produces conditioned place aversion (CPA) in C57BL/6J mice at doses that do 







Figure 5. Nalfurafine produces conditioned place aversion (CPA) in C57BL/6J mice at doses that do not 
reduce morphine CPP. Mice were acclimated to the two-chambered apparatus and allowed to display a side 
preference. Then, mice were treated with saline (in their non-preferred chamber) or drug (in their preferred 
chamber) and confined to that chamber. Vehicle and drug were given on alternate days for four days. On test 
day, the mice were allowed free access to either chamber. The preference for the drug-paired chamber was 





Mice treated with U50,488 displayed a significantly reduced preference for the drug-paired chamber (**, p < 
0.01; ****, p<0.0001, ***,p<0.0004). Vehicle, n=8; 1.25 mg/kg, n=15; 2.5 mg/kg U50, n=9; 5 mg/kg U50,488, 
n= 11. (B) Mice treated with 0.03 mg/kg nalfurafine, but not 0.015 or 0.06 mg/kg nalfurafine, displayed reduced 
preference for the drug-paired chamber. Vehicle, n=20; 0.015 mg/kg, n=8; 0.03 mg/kg nalfurafine, n= 12; 0.06 
mg/kg nalfurafine n=14. Data were analyzed by one-way ANOVA with a Dunnett’s multiple comparisons test 
comparing to vehicle (*) or a Holm-Sidak test to compare between doses of U50,488 or nalfurafine. **, p < 















 3.6.6 Nalfurafine, like the conventional KOR agonist U50,488, reduces morphine-induced 






Figure 6. Nalfurafine, like the conventional KOR agonist U50,488, reduces morphine-induced 
conditioned place preference (CPP) in C57BL/6J mice. Mice were acclimated to the two-chambered 
apparatus and allowed to display a side preference. Then, mice were treated with vehicle (in their preferred 
chamber) or drug (in their non-preferred chamber) and confined to that chamber for 30 or 50 min (for U50,488 





mice were allowed free access to both chambers. The preference for the drug-paired chamber was measured as 
the time spent in the drug-paired chamber minus the time spent in the vehicle-paired chamber. (A) Mice co-
administered morphine (5 mg/kg) and U50,488 (1.25 or 5 mg/kg) displayed reduced preference for the drug-
paired chamber. Morphine alone (+ vehicle), n = 25; Morphine plus U50,488, n = 18-21. (B) Mice co-
administered morphine (5 mg/kg) and nalfurafine (0.015 or 0.06 mg/kg) displayed reduced preference for the 
drug-paired chamber. Morphine alone (+ vehicle), n = 23; Morphine plus nalfurafine, n =18-26. Data were 
analyzed by two-way ANOVA with a Sidak’s multiple comparisons test comparing to preconditioning (*), a 
Dunnett’s test comparing to morphine alone (#), or a Holm-Sidak test to compare between doses of U50,488 or 
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CONCLUSIONS AND FUTURE DIRECTIONS 
4.1 – SNPs identified in a West Virginian population of patients with OUD 
4.1.1 – Significant Results  
Our analysis of a local cohort of patients in treatment for OUD identified several SNPs, out of the 
fourteen tested, with significantly different minor allele frequencies (MAFs) from the reference population. Of 
particular interest to the Siderovski lab is the finding that the rs4606 SNP within RGS2 displayed increased 
prevalence of the minor allele in the test population, given Dr. Siderovski’s role in the first cloning of the 
human RGS2 cDNA in the 1990s (Siderovski et al., 1990; Siderovski et al., 1994; Wu et al., 1995) and first 





within RGS2 has since been associated with anxiety disorders (Smoller et al., 2008; Stein et al., 2014) and 
suicidality (Cui et al., 2008) in humans. Studies of reduced RGS2 expression in mice have also demonstrated 
increased depressive and anxiety phenotypes (Lifschytz et al., 2012). As discussed previously, stress is a 
motivator of drug seeking behavior in rodents and anxiety disorders are commonly associated with substance 
use disorder (SUD) diagnoses (Brady et al., 2013) in humans, providing a plausible rationale for the association 
of the identified RGS2 SNP with the WV OUD patient population.  
The presence of the minor allele of the rs1799971 SNP within OPRM1, has previously been associated 
with increased odds for heroin addiction and decreased analgesic sensitivity (Bart et al., 2004; Tan et al., 2009). 
Assessment of this polymorphism in cell culture shows decreased mu opioid receptor expression yet increased 
affinity for ß-endorphin (Bond et al., 1998) as well as engendering increased heroin self-administration in a 
transgenic mouse model (Zhang et al., 2014). Interestingly, our WV OUD patient population displayed a 
decreased prevalence of this polymorphism compared to the control population. As our patient cohort represents 
a population that is not in active addiction and has begun medication assisted therapy (MAT), this finding may 
indicate an interaction between the rs179971 SNP of OPRM1 and the persistence of active addiction compared 
to the willingness to enter treatment. Comparisons of SNP frequency within a population of active users would 
inform this hypothesis. The Milan Puskar Health Right free clinic in Morgantown runs one of the only needle 
exchange programs in the state of WV. With the goal of reducing the harm related to drug use, the clinic 
provides clean needles and offers counseling to those in active addiction. The needle exchange could be used to 
gain access to a population of active heroin users from the same geographic region as those used for the 
genetics studies presented in this dissertation. Should the minor allele of the rs179971 SNP within OPRM1 
appear with greater frequency in this population of active heroin users than those assessed receiving MAT, it 
may indicate an association of the minor allele with reduced severity of addiction.     
 





The foremost limitations of the present study are the low sample size and restricted patient population. 
Recruitment of treatment centers outside of Morgantown and including additional border states within the 
Appalachian region would allow for both greater statistical power and patient stratification based on ethnicity as 
well as medical history (e.g., first diagnosis of OUD vs. history of OUD). Considering the relationship of the 
kappa opioid receptor to stress (Massaly et al., 2016; Tejeda and Bonci, 2018), inclusion of KOR (OPRK1) 
polymorphisms could provide important insight into the interactions between these two systems. At least one 
study (Kumar et al., 2012) has shown that the rs16918875 polymorphism of KOR increases addiction risk when 
patients also express the A118G (rs1799971) SNP of OPRM1, supporting the need to assess multiple 
components of addiction-related circuitry when assessing addiction risk. In addition, buprenorphine, a MOR 
partial agonist and KOR antagonist, is commonly used in MAT for opioid addiction (Marshalek and Sullivan, 
2010; Zheng et al., 2016). Polymorphisms at KOR may potentially confer variations in the efficacy of 
buprenorphine for this purpose, providing a possible mechanism for screening patients into high and low 
responder groups before beginning therapy. 
 
4.2 – Preclinical assessment of the G protein-biased KOR agonists 
 4.2.1 – Significant Results 
 The findings of these studies support the further investigation of G protein-biased KOR agonists as 
dose-sparing adjuvants to traditional MOR-targeting analgesics. Nalfurafine was shown in vitro to possess 
significant bias towards G protein-signaling at KOR and contrary to the unbiased agonist KOR U50,488, 
augmented the analgesic effect of morphine in the hot plate assay. This augmentation was observed at doses of 
KOR agonist that produced equivalent results in the tail-immersion assay of spinal nociception. As the analgesia 
provided by KOR agonism in the tail immersion assay is G protein dependent (Hernandez et al., 1995; Berg et 
al., 2011; White et al., 2015; Abraham et al., 2018), the augmented analgesia seen in the hot plate assay when 
co-administering nalfurafine with morphine may be a result of decreased b-arrestin signaling emanating from 





 Sedation (as measured in mice by hypolocomotion) and dysphoria (as measured in mice by conditioned 
place aversion) are two effects of KOR agonists that have limited their therapeutic use in humans (Kumor et al., 
1986; Zacny et al., 1994; Walsh et al., 2008). While others have reported a lack of CPA to nalfurafine (Liu et 
al., 2018), our results demonstrate that aversion was present at 0.03 mg/kg nalfurafine, and that locomotion was 
reduced with all tested doses of nalfurafine when given alone or co-administered with morphine. A dose of 
0.015 mg/kg nalfurafine, however, did not produce significant CPA, a result supported by previous work (Liu et 
al., 2018). As all doses of nalfurafine tested produced equivalent augmentation of morphine analgesia in the hot 
plate assay, the possibility remains that further dose optimization to avoid both the sedative and aversive effects 
of nalfurafine may be possible. While the unbiased KOR agonist U50,488 did not produce locomotor sedation 
to as great an extent as nalfurafine, all doses of U50,488 tested produced significant CPA. Taken together, these 
findings suggest that the sedative effects of KOR agonists occur via G protein-mediated signaling, while the 
aversive effects arise downstream of b-arrestin signaling. This interpretation, however, is complicated by work 
utilizing BARR2 knockout mice that display both locomotor sedation and aversion when treated with unbiased 
KOR agonists (White et al., 2015). Further work is needed to determine if these effects truly arise via b-arrestin 
independent mechanisms or if there is compensation via b-arrestin1 in these mice. 
 The effects of nalfurafine on morphine-induced CPP are notable. KOR agonists reduce CPP for a variety 
of drugs of abuse  (Kuzmin et al., 1997; Lindholm et al., 2001; Tsuji et al., 2001; Tao et al., 2006; Morani et al., 
2009a; Ewald et al., 2017a; Townsend et al., 2017a), providing the possible additional benefit of reducing 
addiction liability with a co-administration paradigm. While both U50,488 and nalfurafine reduced morphine-
induced place preference in our studies, each KOR agonist failed to do so with the middle dose of the ranges 
tested; i.e., the dose of each drug that produced the greatest CPA. A reduction in place preference when co-
administering the highest dose of either KOR agonist may be attributable to the induction of cognitive deficits 
known to occur with high doses of KOR agonists (Castellano et al., 1988; Carey et al., 2009), also potentially 
explaining the lack of CPA seen with the highest dose of nalfurafine. The persistence of morphine’s rewarding 





interpretation of the anti-rewarding properties of KOR agonists is that of  positive punishment (Shippenberg et 
al., 1998; Wee and Koob, 2010), or an addition of aversive effects rather than the diminishment of positive 
effects produced by the rewarding drug (negative punishment). Rats pretreated with morphine for five 
consecutive days display an increased place preference for morphine, an effect that is not reduced with the 
addition of the KOR agonist U69593 during pretreatment (Shippenberg et al., 1998). This result supports the 
notion that the rewarding properties of morphine and the aversive properties of U69593 function through 
separate circuits when co-administered, producing a reduced preference at the level of the whole organism 
without altering the underlying biochemical effects of each drug. 
 This theory, however, would predict that doses of KOR agonist producing greater dysphoria (as 
measured by CPA) would produce increased levels of punishment and therefore suppress morphine-induced 
CPP to a greater extent. Our present results indicate the opposite effect, that doses of nalfurafine and U50,488 
producing the greatest aversion reduce place preference for morphine the least. In addition, the lowest dose of 
both drugs (that show reduced levels of aversion) successfully reduced morphine-induced CPP. If KOR agonists 
do indeed reduce CPP through engagement of a punishment circuit rather than inhibition of a rewarding circuit 
engaged by morphine, then timing and intensity of engagement of these circuits may play an integral role in the 
behavioral outcomes observed. Extensive manipulation of dose of both KOR agonist and morphine, as well as 
alterations of pretreatment intervals will be needed as an initial step in investigating the complex interaction 
among the affective responses to each of these drugs. 
 
 4.2.2 – Future Directions 
    The most clinically relevant issue arresting from the results of these studies centers on identifying 
appropriate dose combinations of nalfurafine and co-administered opioid analgesic (Ueno et al., 2013; Kozono 
et al., 2018; Siderovski and Setola, 2018). As nalfurafine is currently used in Japan with a low incidence of 
therapeutically limiting side-effects, clinical investigations into the viability of its use as a dose-sparing 





work supports the possibility that reduced dosing of both morphine and nalfurafine may achieve analgesia 
equivalent to a higher dose of morphine alone, this result needs to be confirmed experimentally by further 
adjusting the dose range of nalfurafine in addition to the dose range of morphine. Other nociceptive assays 
should be included as well to assess for therapeutic relevancy beyond thermal pain. MOR-targeting analgesics 
show reduced efficacy in treating inflammatory and neuropathic pain (Przewlocki and Przewlocka, 2005; 
McAlindon et al., 2014), while these conditions constitute the major reason for chronic out-patient opioid 
prescriptions (Boudreau et al., 2009; Gomes et al., 2011). An increase in the ability to manage these types of 
pain while reducing the likelihood of addiction would be of major therapeutic benefit to the medical 
community. Other therapeutically limiting effects must also be investigated, such as constipation, a side effect 
of MOR agonists prevalent enough to prompt the development of naloxegol (a peripherally restricted MOR 
antagonist) and diuresis, a side effect of KOR agonism (Leander et al., 1985; Webster, 2015). In addition, while 
nalfurafine was shown to reduce acetic acid-induced writhing in mice (a pain-stimulated behavior), it did not 
restore ICSS thresholds depressed by acetic acid administration (a pain-suppressed behavior) (Lazenka et al., 
2018). Furthermore, nalfurafine alone suppressed ICSS thresholds in the absence of a painful stimulus (Lazenka 
et al., 2018). These results seem to indicate that nalfurafine alone does not alleviate the negative affect produced 
by pain, unlike traditional opioid analgesics (Altarifi et al., 2014; Porreca and Navratilova, 2017b), and 
nalfurafine may prevent this positive effect of traditional opioid analgesics when co-administered.  
While these proposed pre-clinical and clinical studies with nalfurafine will better elucidate the viability 
of this drug as a dose-sparing adjuvant, additional experiments are necessary to elucidate the true relevance of G 
protein and b-arrestin signaling in producing the observed effects. Conducting parallel studies with other G 
protein-biased KOR agonists with greater bias factors will inform this question. In addition, future studies using 
BARR2 knockout mice will aid in determining which effects of G protein-biased KOR agonists are dependent 
upon this particular signaling pathway, as well as if any traditionally b-arrestin-dependent effects seen with 
putatively G protein-biased KOR agonists (e.g., CPA to 0.03 mg/kg nalfurafine; Figure 3.6.5 above) are simply 





bias toward G protein signaling in vitro. Such studies would be greatly enhanced with the use of b-arrestin cell-
type and region-specific knockout mice (e.g., (Urs et al., 2016a; Zhu et al., 2017), allowing for more specific 
interrogation of the cell populations and neuronal circuits involved. A deeper understanding of just how MOR 
and KOR produce their euphoric and dysphoric effects, respectively, will hopefully allow for the design of 
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